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Abstract
Clinical utilization of ovulation stimulation to facilitate the ability of a couple to conceive has not
only provided a valuable therapeutic approach, but has also yielded extensive information on the
physiology of ovarian follicular recruitment, endometrial receptivity and early embryo competency.
One of the consequences of the use of fertility enhancing agents for ovarian stimulation has been
the creation of a hyperestrogenic state, which may influence each of these parameters. Use of
aromatase inhibitors reduces hyperestrogenism inevitably attained during ovarian stimulation. In
addition, the adjunct use of aromatase inhibitors during ovarian stimulation reduces amount of
gonadotropins required for optimum stimulation. The unique approach of reducing
hyperestrogenism, as well as lowering amount of gonadotropins without affecting the number of
mature ovarian follicles is an exciting strategy that could result in improvement in the treatment
outcome by ameliorating the deleterious effects of the ovarian stimulation on follicular
development, endometrial receptivity, as well as oocyte and embryo quality.
PART ONE
1 Introduction
Current epidemiological evidence suggests that 15% of
couples will experience infertility. Background prevalence
rates now appear to be reasonably stable, but there is evi-
dence of an increase in the rate of referrals for medical
help [1,2]. Farley and Belsey, 1988 [3], have reported esti-
mates of the prevalence (percentage) of primary infertility
by region and country. They estimated 6% for North
America, 5.4% for Europe, 3% for the Middle East, 10.1%
for Africa, 4.8% for Asia and Oceania, 3.1% for Latin
America and 6.5% for the Caribbean. The American Soci-
ety for Reproductive Medicine (ASRM) estimates that 5
million American heterosexual couples report difficulties
in achieving a viable pregnancy, of which 1.3 million seek
advice for the problem [4].
2 Ovarian stimulation and assisted reproduction for 
infertility management
After correcting the abnormalities detected during the
diagnostic workup, ovulation induction is usually per-
formed either for treatment of anovulation/oligo-ovula-
tion, or empirically in regularly ovulating women. This
approach results in a pregnancy rate of around 8%–15%
per cycle depending on the agents used for ovulation
induction and the characteristics of the couple, such as the
woman's age and the presence or absence of a male factor.
Couples who do not become pregnant with ovulation
induction alone then undergo more sophisticated treat-
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ment modalities including intrauterine insemination
(IUI) and in-vitro fertilization and embryo transfer (IVF-
ET) as a treatment of last resort [5].
Since the birth of Louise Brown in 1978, IVF-ET has
become the therapeutic mainstay for female infertility. It
has become generally accepted as therapy for a wide array
of fertility problems, and has been accompanied by the
rapid expansion of IVF-ET clinics worldwide resulting in
more than 1% of babies being conceived by IVF-ET in
western countries [6].
2.1 Ovarian stimulation for assisted reproduction
In most assisted reproduction programs, gonadotropins
are used alone or in combination to stimulate the growth
and maturation of multiple follicles. This is essential
because of the need to recruit a greater number of follicles,
which provides the opportunity for retrieval of a large
number of oocytes. This would improve the chance for
fertilization of multiple oocytes and thereby allow an
increased number of embryos for transfer in order to give
acceptable success rates. Recent advances in the under-
standing of ovarian stimulation, the techniques of oocyte
retrieval, the handling of gametes, the methods of assisted
fertilization and improved conditions of culture media
have steadily increased the fertilization rate. Fertilization
rates of 60–70% can now be expected when conventional
insemination, or even higher when intracytoplasmic
sperm injection (ICSI) are carried out. However, there has
not been a corresponding increase in implantation rates,
which have remained steady at overall rates around 10%–
15% [6].
2.2 Low implantation rates with assisted reproduction
Throughout the last five decades, a progressive series of
revolutionary techniques have been developed to over-
come infertility, starting with the successful fertilization of
human oocytes in vitro [7] and followed nearly 10 years
later by the birth of the first IVF-ET baby [8]. Several other
new developments in assisted reproduction have
emerged, including cryopreservation and storage of
embryos for later transfer [9], fertilization of oocytes with
a single injected spermatozoon to alleviate severe male
infertility i.e. ICSI [10] and diagnosis of genetic defects
from preimplantation embryos prior to intrauterine trans-
fer [11]. However, although IVF-ET is now a standard,
well-established treatment for infertility, success rates
remain relatively low, with only about 33% of cycles
resulting in pregnancy [12]. This is believed to be due to
the low implantation rate that has not significantly
increased as fertilization rates [13]. Efforts are being made
to improve implantation rates after IVF-ET by improving
culture conditions, optimizing gamete quality and devel-
oping new techniques of selecting viable embryos for
transfer without significant success. For this reason, mul-
tiple embryos are generally transferred to improve preg-
nancy rates, but this has resulted in an unacceptably high
rate of multiple-gestation pregnancies [14].
Although governed by multiple interactive events, embryo
implantation depends mainly on the quality of embryos
and the status of uterine receptivity. During the last two
decades, several developments in controlled ovarian
hyperstimulation [COH], fertilization, and embryo cul-
ture techniques have led to an optimization in the
number and quality of embryos available for ET. In con-
trast, uterine receptivity has failed to benefit from parallel
improvements, and its disarrangement is likely to repre-
sent an important cause of the sub-optimal embryo
implantation rates observed in IVF-ET [15].
2.3 Poor outcome of infertility treatment associated with ovarian 
stimulation
In the following section we review in brief both animal
and human evidence for the unfavorable outcome includ-
ing impaired implantation and increased adverse out-
comes in pregnancies achieved following ovarian
stimulation when compared with spontaneous
pregnancies.
2.3.1 Animal data
Increased pre- and post-implantation embryonic loss has
been reported in mammals [16-21] including rats [16,18],
mice [17-19], murine [20] and hamsters [21], in associa-
tion with ovarian hyperstimulation. These effects have
been attributed to ovarian stimulation using standard
doses of gonadotropins. At higher doses of gonadotro-
pins, studies have found increased frequencies of oocyte
aneuploidy, embryo mortality, fetal growth retardation
and congenital abnormalities [22,23].
The poor outcome after ovarian stimulation has been
attributed to adverse effects on the maternal side and or
the gametes and embryo side. On the maternal side: inad-
equate uterine synchrony or receptivity has been reported.
On the gamete and embryo side, ovarian stimulation has
been found associated with chromosomal defects in the
oocyte leading to increased lethality during the preim-
plantation stages [22,23]. However, because species-spe-
cific variations in implantation strategies exist, these
differences preclude the formulation of a unifying theme
for the molecular basis of this event.
2.3.2 Human data
Many studies have found higher pregnancy rates in donor
oocyte recipients than patients undergoing standard IVF-
ET [24,25]. The higher success rates could be attributed to
better quality oocytes from younger donors. However, in
centers using a shared oocyte system, where the donorReproductive Biology and Endocrinology 2005, 3:54 http://www.rbej.com/content/3/1/54
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keeps half of the oocytes for herself, significantly higher
pregnancy and implantation rates were found in the recip-
ients [26].
Another evidence for adverse effects of ovarian stimula-
tion on implantation is the higher implantation rate asso-
ciated with IVF-ET in the natural or un-stimulated cycle.
Although most studies were associated with a rather high
proportion of cancelled cycles [25–75%] and a low clini-
cal pregnancy rate per started cycle [range 0–23%], higher
implantation rates have been reported (up to 30%) [27].
Adverse Obstetrical Outcome after ovarian stimulation
Induction of ovulation has been shown to raise the risk of
miscarriage when compared with spontaneous pregnan-
cies [28]. This was true even after controlling for advanced
age, a known significant risk factor for miscarriage. Higher
risks as compared with natural pregnancies are reported in
pregnancies after IVF-ET, primarily owing to growth retar-
dation and pre-term birth. Although this can be explained
by the high multiple pregnancy rates in IVF-ET pregnan-
cies [29], an increased rate of small for gestational age and
pre-term birth children is reported in singleton IVF-ET
pregnancies as compared with natural singleton pregnan-
cies after adjustment for potential biases [30-32]. Moreo-
ver, twin pregnancies after assisted reproduction have a
higher rate of perinatal mortality and lower birth weight
as result of a higher rate of premature parturition when
compared to spontaneously occurring twins [33,34]. In
addition, it was reported that women who conceived mul-
tiple gestations through assisted reproductive technolo-
gies have a 2.1-fold higher risk of preeclampsia than those
who conceive spontaneously [35]. Pregnancies associated
with severe ovarian hyperstimulation syndrome have
been found to be complicated with increased miscarriage
rates [36,37]
While ovarian stimulation has been suggested to contrib-
ute, at least in part, for the adverse obstetric outcome
other studies have shown that infertility itself is a factor
that leads to increased obstetric risks and that sub-fertility
is a predictor for low birth weight. Some believe that it is
the cause of infertility itself, rather than the use of ovarian
stimulation, that is the reason behind poor obstetric out-
come after infertility treatment [38,39].
3 Postulated mechanisms behind adverse effects of ovarian 
stimulation
Several causes and targets have been suggested to explain
the poor outcome associated with ovarian stimulation
(Table 1). These include (1) supraphysiological levels of
estrogen, and other steroids and peptides, attained during
ovarian hyperstimulation, (2) the use of exogenous gona-
dotropins as well as other medications applied during
ovarian stimulation such as Gonadotropin releasing hor-
mone (GnRH) analogues (agonists and antagonists),
human chorionic gonadotropin (hCG) and clomiphene
citrate (3) Other possible undetermined factors. These fac-
tors are believed to act through their effects on (i) the
endometrium, (ii) the developing oocyte, (iii) the devel-
oping embryo, (iv) the ovaries and corpus luteum, (v) the
pituitary gland, and (vi) possibly on other targets such as
fallopian tubes, the coagulation system, as well as the
early developing placenta.
3.1 Effect of supraphysiological levels of estrogen
It is believed that the supraphysiological levels of estro-
gen, attained during ovarian stimulation, may explain, at
least in part, for the adverse effects of ovarian stimulation
on the outcome of infertility treatment [40-42]. Different
mechanisms have been suggested for the deleterious
effects of the supraphysiological levels of estrogen
attained during ovarian stimulation Table 2.
Table 1: Postulated mechanisms behind less favorable treatment outcome (reduced implantation rate and increased adverse obstetric 
outcome) after ovarian hyperstimulation
Causes: Targets
1-Supraphysiological estrogen levels attained during ovarian stimulation
2-Medications used during ovarian stimulation:
•Clomiphene citrate
•Gonadotropins
•GnRH analogues: agonists & antagonists
•HCG used to trigger ovulation
3-Other probable causes: abnormal levels of other hormones, peptides 





5-Maternal endocrine system: ovaries (corpus luteum), pituitary gland 
and hypothalamus.




•Coagulation systemReproductive Biology and Endocrinology 2005, 3:54 http://www.rbej.com/content/3/1/54
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Considering all the patients together, significant decreases
in pregnancy and implantation rates were observed when
estradiol (E2) concentrations were > 2500 pg/ml [>9000
pmol/L.] compared with patients having lower E2 concen-
trations. High serum E2 concentrations on the day of hCG
injection in high and normal responder patients, regard-
less of the number of oocytes retrieved and the serum pro-
gesterone concentration were found to be detrimental to
uterine receptivity [42]. Later, it has been shown that a sig-
nificant reduction in the implantation and pregnancy
rates occurred in almost all women with a higher serum E2
concentration of ~5–6000 pg/ml [19–22,000 pmol/L]
[43,44]. Recently, we have presented data showing that
high E2 levels are associated with less favorable treatment
outcome in women undergoing controlled ovarian hyper-
stimulation and IVF-ET [45-51]. We studied the effect of
E2 by looking at the area under the curve (AUC) for E2 lev-
els along the stimulation cycle [45-51]. We believe this is
more accurate than looking at a single measurement of E2
e.g. one day of hCG administration [46]. In addition to
studying the AUC for E2 levels [45,46], we looked at the E2
production per mature follicle and per gonadotropin dose
administered during COH [48] and the effect of age on
these parameters [47]. We found significant correlation
between these parameters and the outcome of IVF-ET
treatment showing that high E2 levels are associated with
lower clinical pregnancy and implantation rates [45-49]
in addition to increased adverse obstetric outcomes
including higher miscarriage rate [49] and lower birth
weight [50]. Successful IVF-ET treatment cycles were asso-
ciated with lower AUC-E2 compared to unsuccessful
cycles at the same patients [49].
3.1.1 Effect of supraphysiological estrogen levels on the 
endometrium
One of the causes for the reduced implantation rates asso-
ciated with ovarian stimulation may be an impairment of
endometrial receptivity, due to high concentrations of sex
steroids. This suggestion is supported by higher implanta-
tion rates in hormonal replacement treatment cycles after
ovum donation, as opposed to the standard IVF-ET cycles
as explained earlier.
Effect on Implantation Window
It is generally believed that the embryo-uterine interac-
tions leading to implantation can only succeed when
embryonic development is synchronized with the prepa-
ration of the endometrium to the receptive state. Typi-
cally, this means that the embryos have reached the
blastocyst stage and that the endometrium has undergone
certain hormone-dependent changes during a specific
time window in the preimplantation phase that prepare it
to be receptive to the developing blastocyst [52].
The concept of endometrial receptivity introduced by Psy-
choyos [53,54], has been shown to last only for several
hours, thereby determining a narrow nidation window.
The concept of an "implantation window" or "receptive
endometrium" was initially established in rodents. In the
rat, the fertilized embryo reaches the uterus on day 4 after
fertilization, and implantation occurs in the afternoon of
day 5 [53,54]. In humans, the ovum is fertilized in the fal-
lopian tube, arrives in the uterine cavity around day 17
(day 14 is taken as day of ovulation of a 28-day cycle), and
remains there as a free-floating embryo until about day
19; implantation then occurs between days 19 to 22
[55,56]. However, the precise timing and molecular basis
of the receptive window in the human remain undefined.
Unfortunately, endometrial receptivity knowledge in the
human is limited due to the obvious experimental draw-
backs and the lack of specific criteria to define a receptive
endometrium.
In the literature, there is controversy regarding the effect of
ovarian stimulation on endometrial development. Most
of the investigators have reported adverse effects of high
estrogen levels on endometrial development but there
was no consensus on the actual effect. Some have shown
endometrial advancement [57-61] while others showed
endometrial retardation [62,63]. However, all studies
confirm direct deleterious effects on the endometrial
development that jeopardize the chance of implantation
Table 2: Deleterious effects of the supraphysiological estrogen 
levels attained during ovarian stimulation:
1-Effect on the endometrium: most of the available evidence
a: Dys-synchronization of the implantation window.
b: Abnormal Temporal expression of the endometrial pinopodes.
c: Defective endometrial estrogen and progesterone receptors.
d: Impaired endometrial blood flow
e: Abnormal endometrial integrins expression
2-Effect on the developing oocyte
a: Effect on chromosomal and cytogenetic integrity of the oocyte
b: Effect on the mitochondrial function
3-Effect on the sperm causing possible premature acrosome reaction 
and deactivation
4-Effect on the developing embryo and blastocyst hatching
5-Effect on the ovaries and pituitary (defective corpus luteum function 
and luteal phase):
a: Defective LH secretion:
- Abnormal LH surge
- Abnormal LH tonic pulse
b: Defective corpus luteum function
6-Other probable targets:
I-Leptin
II-Coagulation system: III-Fallopian tubes
• a: Effect on the ductal environment and ductal fluid
• b: Effect on the ductal transfer and motility
IV-Early developing placentaReproductive Biology and Endocrinology 2005, 3:54 http://www.rbej.com/content/3/1/54
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due to the lack of synchronization between the develop-
ment of the endometrium and the early embryo develop-
ment. Implantation failure has been suggested to result
from the disparity in maturation between the endometrial
stroma and the epithelium observed in histology. Since a
paracrine communication between the epithelium and
the stroma may be important at the beginning of implan-
tation, this disparity could compromise uterine receptivity
or early trophoblastic invasion [64,65].
The effect of high E2 concentrations (> 20,000 pmol/L)
was found to be associated with gland-stromal dys-syn-
chrony, which indicated a deficient secretory transforma-
tion of the endometrium that represents a sub-optimal
endometrial environment for implantation. This finding
substantiates clinical observation of significantly lower
pregnancy rates in IVF-ET cycles of women with high E2
concentrations. In these patients, there was a marked stro-
mal edema associated with a significantly greater number
of stromal vessels, which suggested advanced stromal
maturation [44].
In these studies, definitions of supraphysiological hormo-
nal concentrations were variable. Also, the timing of the
biopsies and the drug regimens used for ovarian stimula-
tion were different. This, in addition to the variation in
endometrial response to different E2 concentrations, may
explain the disagreements reported in the literature [66].
Moreover, both the premature progesterone serum eleva-
tion, which occurs in 30% of stimulated IVF-ET cycles
before hCG administration, and the advanced post-ovula-
tory rise in progesterone serum concentrations are
believed to be responsible for the advanced endometrial
development associated with ovarian stimulation [67,68].
However, other studies failed to confirm these observa-
tions [69,70].
Effect on endometrial pinopodes
At the time of implantation, the apical membranes of the
epithelial cells lining the uterine cavity develop large and
smooth membrane projections, named pinocytes due to
their pinocytotic function [71]. Their development is pro-
gesterone-dependent with strict correlation with the
implantation window in the rodents [72]. Similar struc-
tures have been seen in the human endometrium [73].
The number of pinopodes was found to have a strong cor-
relation with implantation after embryo transfer [74,75].
Hormonal treatment has been shown to be associated
with changes in the timing of pinopode formation. Dur-
ing ovarian stimulation with clomiphene citrate followed
by human menopausal gonadotropins (hMG)/hCG, fully
developed pinopodes were found 2 to 3 days earlier [76].
In contrast, with E2 and progesterone treatment, fully
developed pinopodes were found to be about two days
later. Pinopodes were found to form as early as 4 days
after hCG administration [59].
Nikas et al. [61], studied the temporal expression of
pinopodes as a specific marker for receptivity in IVF-ET
cycles induced by gonadotropins, compared to women
with regular menstrual periods and proven fertility who
served as controls. They did not find ovarian stimulation
to affect endometrial pinopode formation in terms of
quantity and life span. Instead, the cycle days when
pinopodes formed were specific to the individual, being
on average 1–2 days earlier in cycles with ovarian stimula-
tion than in natural cycles. These changes in pinopode
expression may reflect shifts in the window of receptivity,
resulting in ovo-endometrial asynchrony and limiting
implantation success in IVF-ET [61]. In IVF-ET, embryonic
development is probably delayed while the uterus is
advanced, resulting in an early closure of the nidation
window, before the embryo eventually reaches a stage
capable of initiating implantation. These findings support
the theory that reduced implantation rates in IVF-ET
cycles could result from impaired or premature endome-
trial maturation.
Effect on estrogen and progesterone receptors in the endometrium
A lack of estrogen receptors (ER) has been reported [77]
during ovarian stimulation cycles that rendered the
endometrium functionally hypoestrogenic or hypopro-
gestogenic. Also, it has been reported that the expression
of progesterone receptors (PR) in the endometrium was
decreased in the early part of luteal phase after ovarian
stimulation [78]. This premature PR decrease was consist-
ent with an early high progesterone level [79]. Papan-
ikolaou et al. [80], investigated prospectively the effect of
multi-follicular ovarian stimulation for IVF on the late fol-
licular phase endometrium histology and the expression
of ER and PR. Endometrial biopsies were taken in a natu-
ral cycle on the day of the onset of the surge of the LH, and
in a subsequent stimulation cycle on the day of hCG
administration for final oocyte maturation. Histological
examination of biopsies both in natural and stimulated
cycles showed no secretory changes. However, in stimu-
lated cycles, PR expression was significantly up-regulated
compared to natural cycles in both glands (1.67 versus
1.34, P < 0.05) and stroma (1.98 versus 1.62, P < 0.05),
whereas ER was down-regulated in glands (1.15 versus
1.43, P < 0.05). In IVF cycles, the progesterone measure-
ments, although within normal values (range 0.8–1.4
microg/l), were significantly higher than in natural cycles
(0.99 vs 0.63 microg/l, respectively, P = 0.008). An ongo-
ing pregnancy rate of 37.5% was achieved in the stimu-
lated cycles. The authors concluded that although the
current study found no early secretory transformation in
stimulated endometria before hCG administration, the
ER and PR expression in these endometria was similar toReproductive Biology and Endocrinology 2005, 3:54 http://www.rbej.com/content/3/1/54
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the one described during the first days of the luteal phase
in natural cycles. Supraphysiological concentrations of
estradiol and subtle progesterone rises in the late follicu-
lar phase might be responsible for this modulated steroid
receptor profile. They added that this phenomenon indi-
cated accentuated maturation of the endometrium in IVF
cycles from the pre-ovulatory phase onwards. [80].
Ovarian stimulation with GnRH-agonist/hMG was found
to induce precocious secretory endometrial transforma-
tion around the time of oocyte retrieval. Compared to nat-
ural cycles, there was an imbalance between endometrial
steroid receptor content, proliferation index, and matura-
tion in the peri- and postovulatory phases of stimulated
cycles. The lower ER in stimulated cycles on the day of
oocyte pick up as compared to the natural cycle controls
on the day of ovulation was mainly observed in the
stroma, but failed to reach a significant difference in the
glands. As for PR, the staining intensity of the stromal ER
in the stimulated cycles was higher than that of luteal
phase day 2 of a natural cycle. These findings suggest a rel-
ative imbalance in ER and PR content of the endometrium
in stimulated cycles compared to their natural cycle coun-
terparts. [79].
In conclusion, excessive ovarian response was suggested
to lead to insufficient secretory transformation of the
endometrium, as well as discordant glandular and stro-
mal development at a time that coincides with the period
of maximum uterine receptivity.
Effect on endometrial vasculature and endometrial blood flow
Angiogenesis has a critical role in female reproductive
physiology. Growth of the endometrium and placenta-
tion is also accompanied by extensive angiogenesis. Thus,
an actively maintained blood supply is an essential
requirement for reproductive functions, including normal
implantation [81]. Endometrial vasculature has been
shown to play a prominent role in the early endometrial
response to the implanting blastocyst, and vascular
changes may contribute to uterine receptivity [82].
The introduction of transvaginal Doppler ultrasound
makes the measurement of uterine artery blood flow pos-
sible, and at one time it was hoped that uterine arterial
resistance changes might reflect uterine receptivity [83].
Applebaum first introduced the concept of evaluating
uterine receptivity by a uterine score including the
endometrial blood flow [84]. Different studies have dem-
onstrated significant changes in the Doppler indices of
uterine and ovarian vessels during ovarian stimulation
and spontaneous cycles [85,86]. Basir et al., found evi-
dence of impaired endometrial blood flow in association
with significantly high estrogen levels in high responders
to ovarian stimulation [87].
Although pregnancy outcome tended to be poor in
patients with higher mean uterine arterial impedance
indices, the predictive value of using a specific resistance
index (RI) or pulsatility index [PI] variable in assessing
endometrial receptivity seems to be limited [88]. One of
the explanations is that the major uterine compartment is
the myometrium and not the endometrium, and thus
most of the blood passing through the uterine arteries
never reaches the endometrium. A more logical approach
would be to evaluate the vascularization around the
endometrium directly in an attempt to assess endometrial
receptivity.
Histological studies have confirmed that the sub-endome-
trial halo surrounding the endometrium represents the
innermost layer of the myometrium, and compared with
the outer myometrium, it consists of a distinct compart-
ment of more tightly packed muscle cells with increased
vascularity. Studies have shown that interactions between
the junctional zone and the endometrium may play an
important role in the implantation process [89,90] and
endometrial-sub-endometrial blood flow distribution
pattern assessed by transvaginal color Doppler before ET
was found to correlate with the implantation and preg-
nancy rate after IVF-ET [91]. With the absence of sub-
endometrial blood flow, even in the presence of other
favorable parameters, no conception was achieved. By
using a similar approach, Salle et al., calculated a uterine
score in the secretory phase of the menstrual cycle preced-
ing IVF-ET [92]. Immunocytochemistry study revealed
that the sub-endometrial myometrium, also called the
junctional zone myometrium or archimyometrium,
exhibits a cyclic pattern of estrogen and PR expression that
parallels that of the endometrium [93]. Moreover, the
responsiveness of the junctional zone has been shown to
be associated with implantation success during IVF-ET
treatment [90].
Many investigators have also noted the correlation of
junctional zone contractions with pregnancy outcome in
both natural [94] and assisted reproduction cycles [95].
Less-active junctional zone contractility is associated with
higher pregnancy rates
Kupesic et al. compared the 2-D and 3-D ultrasonographic
scoring systems by combining parameters including
endometrial thickness, volume, echogenicity, and sub-
endometrial blood flow. They found the two systems had
similar efficiencies in predicting pregnancy outcome of
IVF-ET procedures [96]. Several investigators noticed that
when the endometrial and sub-endometrial flow parame-
ters were combined, significant differences were found
between pregnant and nonpregnant patients [97-99]. In
contrast, there was no significant difference if attention
was only focused on intraendometrial or sub-endometrialReproductive Biology and Endocrinology 2005, 3:54 http://www.rbej.com/content/3/1/54
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blood flow [100]. These results imply that the endome-
trial/sub-endometrial area must be considered as a whole
in evaluating endometrial perfusion.
One hallmark of implantation is increased vascular per-
meability at the implantation site. Vasoactive agents,
including histamine, platelet-activating factor, vascular
endothelial growth factor, and eicosanoids, have been
studied during implantation [101,102]. Vaginal E2
administration improves endometrial proliferation and
uterine perfusion, presumably because of combined local
and systemic effects, but may interfere with P-induced
uterine relaxation [103].
In a study by Basir et al., [104] the investigators compared
the hemodynamic parameters of the utero-ovarian vascu-
lature and the endometrial spiral arteries of women who
showed a moderate response with women whose E2 con-
centrations were in excess of 20,000 pmol/l after ovarian
stimulation. Despite low uterine PI and RI, the endome-
trial blood flow in high responders appears to be
impaired. The authors concluded that this might contrib-
ute to the decline in implantation efficiency noted in high
responders. The decreased endometrial blood flow
despite the increased blood flow in the uterine arteries
may indicate a shunt of blood flow from the
endometrium into the myometrium.
The authors [104] found low pulsatility index and resist-
ance index of the ovarian arteries indicating neovasculari-
zation and increased capillary permeability in the ovarian
tissue of high responders. The authors suggested that the
blood flow might be directed through the utero-ovarian
collaterals to the ovaries. However, because the sample
size in this study was small (19 patients with E2 > 20,000
pmol/L), further larger prospective studies are required to
confirm the effect of excessively high concentrations of
serum E2 on endometrial blood flow.
Moreover, the increase in hormonal concentrations in the
peripheral plasma leads to a decrease in peripheral vascu-
lar resistance [105] and a decreased contractility of the
uterine muscles. This results in relaxation and opening up
of the small uterine vascular channels, which may also
cause an increase in the capillary permeability. In a study
on the endometrial morphological changes at high con-
centrations of E2, a significantly greater number of vessels
and endometrial edema in women who responded exces-
sively to ovarian stimulation was demonstrated. There-
fore, it was postulated that the blood flow through these
minute endometrial vessels may be very slow and the
weak Doppler flow signals arising from them could not be
picked up by the color Doppler despite low uterine PI and
RI. The increase in capillary permeability and dilatation
leads to extravasation of fluid from the intercellular to
extracellular compartments, and hence endometrial
edema [106]. In another study the investigators suggested
that the blood flow per capillary might actually be
reduced during edema [107].
Successful implantation and continuing development of
implanted embryo depends on a complex series of cellu-
lar and molecular events between the blastocyst and the
endometrium [108]. The decline in blood flow could
therefore impede the exchange of essential nutrients, bio-
active molecules and reactive compounds that are vital for
implantation with absent endometrial and intra-endome-
trial vascularization appeared to be a useful predictor of
failure of implantation in IVF-ET cycles [109].
Whether fertilization occurs in vivo or in vitro, most
human embryos will not develop through gestation [110]
with a very high proportion of developmental failure dur-
ing the preimplantation stages associated with chromo-
somal defects of oocyte origin [111]. Van Blerkom
suggested that the dissolved oxygen content of pre-ovula-
tory follicular fluid and the developmental competence of
the corresponding oocyte were related [112]. A develop-
mentally significant association between the chromo-
somal normality of the human oocyte and the level of
intra-follicular oxygen and peri-follicular vascularity was
reported suggesting that hypoxic intra-follicular condi-
tions that result from the failure of an appropriate micro-
vasculature to develop around the growing or pre-
ovulatory follicle(s) could be a proximate cause of the
maternal-age-related increase in the incidence of trisomic
conditions [112-114].
Effect on Integrins
Integrins are a family of cell adhesion molecules. Previous
work has shown the expression of integrins in the
endometrium changes during the menstrual cycle [115].
Three integrins in particular (1β1, 4β1 and vβ3) are thought
to play a vital role in implantation as all are expressed dur-
ing the 'implantation window'. The β3 and β1 integrins
have also been shown to be reduced in infertile patients
using flow cytometry [116]. Aberrant patterns of integrin
expression have also been associated with certain diag-
noses in infertile patients, including luteal phase defects,
endometriosis, hydrosalpinx and unexplained infertility
[117].
The exact role of integrins remains controversial and
results have not been duplicated in all studies. Creus and
co-workers showed no difference in integrin expression in
patients who became spontaneously pregnant compared
with those that do not [118]. Thomas et al., demonstrated
that integrin expression seems to be reduced in the glan-
dular epithelium in the endometrium after ovulation
induction, irrespective of the dating. The authors con-Reproductive Biology and Endocrinology 2005, 3:54 http://www.rbej.com/content/3/1/54
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cluded that there might be an ideal E2 level that should be
reached during IVF-ET treatment as low estrogen levels
might reduce the yield of oocytes, but high levels might
impair the receptivity of the endometrium reducing
integrin expression and leading to lower implantation
rates [119].
3.1.2 Effect of supraphysiological estrogen levels on the developing 
oocyte (follicular and oocyte development)
As the contributor of the bulk of the cytoplasm to the
zygote and half of its nuclear DNA, the key importance of
the oocyte is unquestionable. The principle, that embryo-
genesis is rooted in oogenesis, has been understood for
nearly a century, and is now becoming better understood
at the molecular level. During follicular growth, the
oocyte is in close contact with granulosa cells through gap
junctions and is therefore under the influence of the fol-
licular environment. Since oocyte maturation is such a
long process, any adverse events occurring during this
period can damage vital structural molecules or whole
organelles, resulting in oocytes with reduced developmen-
tal competence. These oocytes may in turn give rise to pre-
implantation embryos with a compromised viability, and
hence, a reduced implantation potential [120]. The ER
gene is expressed in the human cumulus-oocyte com-
plexes and oocytes but not in granulosa/cumulus cells
which might suggest a lack of receptor-mediated autocrine
effect of estrogen during folliculogenesis. Conversely,
estrogen secreted by granulosa/cumulus cells, may exert a
paracrine effect to influence oocyte maturation and fertili-
zation competence directly [121]. It was reported that
retrieval of >10 oocytes during IVF-ET cycles was corre-
lated with oocytes of lower quality, as manifested by a
decrease in the fertilization rate [122].
Effect on the chromosomal structure and cytogenetics of the oocytes
Studies with animal systems have indicated that a single
cycle of ovarian stimulation can have adverse effects on
oocyte competence during early development, and may
well have downstream effects on the normality of fetal
growth and development. Whether developmental defects
could result from chromosomal malsegregation during
ovarian stimulation-induced meiotic maturation has been
examined in the mouse system. Earlier studies compared
oocytes obtained after spontaneous or hormonally
induced ovulation and found no increase in the incidence
of non-disjunction or oocyte aneuploidy after ovarian
stimulation [123]. In contrast, cytogenetic analysis of pro-
nuclear stage mouse eggs after single cycle of ovarian stim-
ulation showed chromosomal aberrations largely
confined to the female pronucleus, indicating develop-
mental compromise prior to fertilization [124]. Sengoku
and Dukelow found comparable frequencies of aneu-
ploidy for cleavage-stage hamster embryos produced in
natural and pregnant mare serum gonadotropins
(PMSG)-stimulated cycles, indicating that peri-implanta-
tion mortality may have an epigenetic origin [125].
In IVF-ET programs, the high rate of oocyte recovery and
successful fertilization in vitro contrasts with a relatively
high rate of conception failures, as even the most
advanced IVF-ET clinics can provide a 33% success rate per
cycle at best [12], despite multiple embryo transfers. The
possible reason for this conception failure is the high fre-
quency of lethal chromosomal abnormalities that pre-
vents embryonic development beyond the pre- and post-
implantation stages. The high frequency of spontaneous
abortions also indicates that the proportion of embryos
with genetic defects is significant. Cytogenetic analysis of
the early stages of cleavage indicates that chromosomal
aberrations may be found in 35–44% of pre-implantation
embryos produced in vitro [126]. It has to be emphasized
that the majority of pre-implantation embryos carry
numerical chromosomal defects. However, the high inci-
dence of chromosomal anomalies is presumably biased
by the fact that only embryos with a poor morphological
score were analyzed (discarded embryos). It nevertheless
indicates that the low implantation rates of human pre-
implantation embryos in IVF-ET programs are the conse-
quence of natural selection [127]. Aneuploidy is the most
common abnormality found in normally developing
embryos following ovarian stimulation and IVF-ET [128],
but other aberrations were also revealed. Polyploidy and
multinucleation were frequently described in arrested
embryos
Estrogen is well known to induce chromosomal and
cytogenetic damage. The natural hormone E2 has clearly
been shown to induce alterations in chromosome
number such as losses or gains of whole chromosomes
[129,130], chromosome translocations [131,132], and
gene amplifications [133,134]. In addition, there is pre-
liminary evidence of estrogen-induced gene mutations
and gene deletions [135,136].
The synthetic estrogen, diethylstilbestrol (DES) causes a
severe yet reversible deterioration of meiotic spindle
microtubule organization during maturation of the
mouse oocytes [137]. High doses of E2 were found to
induce numerical chromosome changes (both chromo-
some gains and losses) similar to the reported observa-
tions with the synthetic estrogen, diethylstilbestrol [129].
Estrogen is also known to cause direct DNA damage via its
catecholestrogen metabolites [138,139]. There are several
types of free radical-mediated DNA damage, which are
induced by estrogens and/or their metabolites [140-142].
As explained earlier, supraphysiological estrogen levels
associated with ovarian stimulation impair the uterovar-
ian blood flow resulting in follicular hypoxia. GauldenReproductive Biology and Endocrinology 2005, 3:54 http://www.rbej.com/content/3/1/54
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proposed that follicular hypoxia might have a potent
adverse influence on spindle organization and the nor-
mality of chromosomal segregation in the human oocyte
[143].
Effect on the mitochondrial function of the oocytes and embryos
Van Blerkom has suggested that the developmental com-
petence of mouse and human early embryos is related to
the metabolic capacity of the mitochondria. It is thought
that mitochondrial replication does not begin until after
implantation, and that paternal contribution is minimal.
Therefore the preimplantation embryo is completely reli-
ant on maternally inherited mitochondria in the oocyte.
Deletions and mutations in oocyte mitochondrial DNA
may lead to mitochondrial dysfunction, influencing
energy production and apoptosis in oocytes and early
embryos, resulting in aberrant chromosomal segregation
or developmental arrest [144].
The classical model of E2 action has been described to be
mediated by cytoplasmic/nuclear partitioning receptor
proteins that stimulate gene transcription upon binding
to specific DNA sequences [145]. However, there are
increasing functional evidences for extra nuclear/cytoplas-
mic localization of steroid hormone receptors. Several
studies showing rapid non-genomic actions of steroids
have led to speculate about the existence of cell-surface
resident receptor forms [146-148]. Reports have docu-
mented the presence of estrogen binding proteins local-
ized at the plasma membrane [149,150]. Independently,
the known direct effects of various steroids on mitochon-
drial gene transcription support the idea of receptor
attachment to the mitochondrial genome [151]. It was
also identified early that estrogen specific binding sites
were associated with mitochondrial and microsomal
structures [152].
The mitochondrial-enriched subfraction represented an
important source of E2 binding, where the steroid was rec-
ognized in a stereospecific and high affinity manner. The
existence of mitochondrial and membrane estrogen bind-
ing sites correlated with the presence of ER but mainly
with ER proteins. Using macromolecular E2 derivatives in
Ligand Blot studies, both mitochondrial and membrane
estrogen binding proteins were found in the uterus, and
the ovary. This differential cellular partitioning of ER and
forms may contribute to the known diversity of E2 effects
in target organs [153].
Recently, in myocardial cell model, it was reported that at
physiological concentrations, which do not inhibit mito-
chondrial functions, estrogens can protect heart mito-
chondria from the loss of cytochrome c induced by high
calcium, and this might be one of the possible mecha-
nisms by which estrogens preserve myocardial cell viabil-
ity after ischemia/reperfusion [154]. High concentrations
of estrogens (50–100 M) have been found to have a dam-
aging effect on mitochondrial functions by strongly inhib-
iting mitochondrial respiration and membrane potential
presumably due to decreased activity of the respiratory
chain. The inhibition of the respiratory chain may be due
to non-specific binding of estrogens to hydrophobic
regions of the mitochondrial membranes, which may
change protein/lipid interactions, disturb electron trans-
port through the inner mitochondrial membrane and
reduce membrane potential [155].
We postulate that supraphysiological levels of estrogen
attained during ovarian stimulation may affect the mito-
chondrial function of the developing oocyte and embryo.
This could be one of the mechanisms behind impaired
developmental capacity of the oocytes and embryos
obtained after ovarian stimulation.
3.1.3 Effect of supraphysiological estrogen levels on the spermatozoa 
and sperm/oocyte interaction
Sperm are exposed to estrogens within the male tract, and
P450 aromatase has also been identified in human sper-
matozoa [156]. This raises the possibility that the sperma-
tozoa can provide a continuing local source of estrogens
in the epididymis, as well as while in the female tract on
its journey to fertilize the oocyte. Inside the female genital
tract, the spermatozoa would also be exposed to estro-
gens, particularly in tubal fluid following follicle rupture
and when in close vicinity to released oocytes [157].
Estrogen receptors in the spermatozoa
Non-genomic effects of estrogens have also been reported
in several cell types including the spermatozoa [158].
Immunohistochemical detection of ER has been reported
for human spermatozoa, with distribution in both the
head and flagellum [159].
Possible effect of estrogen on the spermatozoa function
After ejaculation, in vitro, the spermatozoa are initially
unable to fertilize [160]. The spermatozoa acquire the
capacity to fertilize, after a certain period of time that is
species-specific when exposed to an appropriate environ-
ment either in vivo or in vitro. This process is called
'sperm capacitation' [161]. Capacitated spermatozoa are
able to express hyperactivated motility, to undergo the
acrosome reaction, and to fertilize an oocyte [160]. Estro-
gens are believed to have a possible effect on these events
(capacitation and acrosome reaction), which would have
important consequences on fertility in vivo.
Recently, Adeoya-Osiguwa provided evidence that E2 and
environmental estrogens can significantly stimulate mam-
malian sperm capacitation, acrosome reactions. They
found that in uncapacitated cells, E2 at 00.001 µmol/l, sig-Reproductive Biology and Endocrinology 2005, 3:54 http://www.rbej.com/content/3/1/54
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nificantly stimulated capacitation and acrosome reactions
while in capacitated cells, E2 had no effect. The authors
concluded that whether these responses have effects on
fertility in vivo remains to be determined, along with the
mechanisms of action involved [157]. It is pertinent to
mention here that the average E2 concentrations in follic-
ular fluid from mature oocyte are in the micromolar range
[162,163].
The regulation of capacitation is very important in mam-
malian fertilization as evidence suggests that once capaci-
tation has been initiated it will usually continue
unchecked, frequently resulting in the spermatozoa
undergoing spontaneous acrosome reactions and thus
becoming non-fertilizing [164].
Adeoya-Osiguwa argued that E2 and the environmental
estrogens appear primarily to stimulate the spermatozoa,
accelerating the rate of capacitation and then promoting
'over-capacitation' in at least some of the cells, resulting in
the acrosome reaction [157]. Since already acrosome-
reacted spermatozoa are non-fertilizing [160], similar
responses occurring in vivo could reduce the number of
potentially fertilizing cells and so have an undesirable
effect on fertility. As capacitation and fertilization occur in
the female reproductive tract, it is likely that any effects of
environmental estrogens on sperm function would be
more pronounced in the female, but effects on mature
spermatozoa awaiting ejaculation cannot be ruled out.
3.1.4 Effect of supraphysiological estrogen levels on the embryo
Mouse and human embryos, when cultured in vitro,
undergo a delay in development compared with those
grown in vivo. This delay can be caused by suboptimal
culture conditions, but possible influences of ovarian
stimulation cannot be excluded [165]. In order to deter-
mine if implantation failure associated with ovarian stim-
ulation was due to abnormalities in the blastocysts or the
endometrium, decidualization studies and embryo trans-
fers to pseudopregnant recipients were performed
[166,167]. The uterus of a large proportion of superovu-
lated animals was unable to undergo decidualization in
time, whereas embryo transfers to pseudopregnant
females resulted in normally developing fetuses, which
indicated that hormonally treated oocytes themselves
were not affected. Some studies found that the E2 concen-
trations in the fresh cycle were not related to the success of
frozen-thawed embryo transfer cycles indicating that
embryo quality seemed unaffected by the high estrogen
levels [168,169]. However, there is increasing evidence
suggesting that ovarian stimulation and the associated
high estrogen levels are detrimental on the embryo and
associated with a decrease in the fertilization rate. When
compared with blastocysts derived from naturally cycling
mice, blastocysts that developed in vivo in superovulated
mice were found to have fewer microvilli on their surface
[170], a reduced [35S]-methionine uptake [171], and a
lower cell number and mitotic index [172]. A reduced cell
number and a two-fold decrease in viability post-transfer
of embryos from gonadotropins-stimulated hamster
females, was also observed [21]. Furthermore, it has been
reported that the proportion of abnormal preimplanta-
tion embryos increases after superovulation, and that
blastocysts have a smaller trophoblastic outgrowth in
vitro [173]. Moreover, in mice as well as in humans, there
is evidence for steroids being regulators of gene expression
in the embryo and endometrium, and that embryo mor-
phology and rate of development – both of which reflect
embryo quality – have a genetic basis. Also, ovulation
induction therapy has been found to be associated with
an increased rate of mosaicism in the embryos, which fail
to implant [52].
It has been proposed that high E2 levels after COH impair
endometrial receptivity because oocyte quality, fertiliza-
tion rate, and embryo cleavage (until day 2) were normal
in patients with a high response [174] and the quality of
embryos and the implantation rate seemed normal in
subsequent frozen-thawed embryo transfer [43]. How-
ever, high E2  levels were found to be deleterious to
embryo adhesion in vitro, mainly because they have a
direct toxic effect on the embryo that may occur at the
cleavage stage [175].
Mouse and human embryos, when cultured in vitro,
undergo a delay in development compared with those
grown in vivo. This delay can be caused by suboptimal
culture conditions, but possible influences of ovarian
stimulation cannot be excluded. In the mice, preimplan-
tation embryonic development in vitro and in vivo was
found to be negatively influenced by the ovarian stimula-
tion itself, and results in an impaired blastocyst formation
and fetal growth retardation at day 14 of gestation. The
authors suggested that a similar negative effect of ovarian
stimulation on oocyte and embryo quality seems likely in
IVF-ET which might explain in part for the delay in embry-
onic development after IVF-ET, and for the low birth
weight often observed after assisted reproductive technol-
ogies [165].
Effect of estrogen on blastocyst hatching
The successful hatching of the embryos is thought to be a
key event in the implantation process. One reason for the
low implantation rate that has been suggested is the lim-
ited ability of blastocysts to hatch from the zona pelluc-
ida. Suboptimal culture conditions might induce the
hardening of zona pellucida, which could limit the hatch-
ing ability of embryos [176]. To help embryos hatching
from their zona pellucida during blastocyst expansion,
different types of assisted hatching have been developed,Reproductive Biology and Endocrinology 2005, 3:54 http://www.rbej.com/content/3/1/54
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including mechanical partial zona dissection or zona
drilling, chemical zona drilling with acidic Tyrode's solu-
tion, and the laser dissection technique [177]. However,
there is controversy about the benefit of assisted hatching
on the improvement of the implantation rate and preg-
nancy rate. Some agreed as to the benefit of assisted hatch-
ing in women with advanced age, in women with repeated
IVF-ET failure [178].
The degree of zona pellucida thickness variation of the
transferred embryos has been found to exhibit a strong
correlation with clinical pregnancy outcome following
IVF-ET treatment and to be important for embryo selec-
tion during clinical transfers [179,180]. Zona pellucida
thickness variation and character were found to correlate
with implantation. Implantation rates were found to
range from 10% for embryos with uniform thickness to
29% with thin or irregular zona pellucida [181,182].
These reports suggested that patients transferred with
embryos with thinner zonae had a better chance of suc-
cessful implantation and pregnancy as compared to those
transferred with embryos having thicker zonae. Other
reports have proposed zona pellucida thickness variation
as a reliable marker for selecting thawed as well as fresh
human embryos for transfers [183,184]. Cohen [185]
conducted a retrospective analysis of zona pellucida thick-
ness of transferred embryos through video recordings and
concluded that the variations in zona pellucida thickness
rather than the zona pellucida thickness per se of the
transferred embryos was a stronger predictor of the IVF-
ET.
A significant linear relationship was reported to exist
between the mean zona pellucida thickness of each
patient and the maximum E2 level and an increasing one
with the hMG dose. The authors found that the zona pel-
lucida thickness was basically an individual feature that
influenced the fertilization rate [186].
3.1.5 Effect of supraphysiological estrogen levels on the ovaries 
[corpus luteum], pituitary, and hypothalamus
Abnormalities in the luteal phase have been shown in vir-
tually all the stimulation protocols used in ovarian stimu-
lation, on the hormonal, as well as on the endometrial
level. All three aspects of a defective luteal phase, that is, a
shortened luteal phase and/or low mid-luteal serum pro-
gesterone concentrations and/or abnormal endometrial
histology, have been regularly observed in IVF-ET cycles.
For that reason, luteal-phase supplementation with hCG
or progesterone increases pregnancy rates, and its neces-
sity has been well established, at least in GnRH-agonist
cycles [187].
In the 'pre-agonists era', Edwards and Steptoe were the
first to postulate luteal phase inadequacy resulting from
ovarian stimulation as a cause of failure of IVF-ET cycles.
With the introduction of the GnRH-agonist, used in ovar-
ian stimulation cycles to avoid premature luteinizing hor-
mone [LH] surge, luteal phase inadequacy was reported. A
meta-analysis of different clinical trials demonstrated
beneficial effects of luteal support when ovarian stimula-
tion was carried out with human menopausal gonadotro-
pins [hMG] in association with GnRHa [187].
Recently, GnRH antagonists have become available for
clinical use. Whether GnRH antagonists induce down-reg-
ulation of pituitary GnRH receptors is still a subject of
investigation [188]. It has been demonstrated that chronic
administration of the GnRH antagonist Cetrorelix in rats
causes an important down-regulation of pituitary GnRH
receptors [189].
Direct effect on corpus luteum
Different estradiol receprors have been detected in human
corpus luteum, indicating that estrogen might be a local
regulator of corpus luteum function [190]. In the pre-ago-
nist era, the alteration of the Estradiol/progesterone (E2/
P) ratio was considered a main cause of luteal-phase inad-
equacy, possibly through the luteolytic action of E2 [5]
Estrogen is thought to exert a direct luteolytic action in
primates as exogenous administration of E2 reduces pro-
gesterone concentrations during the luteal phase [191],
probably via inhibiting the enzyme 3 beta-hydroxysteroid
dehydrogenase, which is mandatory for progesterone syn-
thesis [192]. Moreover, although the exact mechanism
has not yet been established, estrogen may play a role in
the regulation of proteins involved in the process of
luteal-cell apoptosis [193].
Normal corpus luteum function is dependent on the
proper function of the pituitary gland and hypothalamus.
Adequate luteinizing hormone [LH] surge during ovula-
tion and continuous tonic LH pulses during the luteal
phase are necessary for the proper development of the cor-
pus luteum. Corpus luteum dysfunction due to the effect
of ovarian stimulation on the pituitary gland and hypoth-
alamus will be discussed later.
Effect on the pituitary gland and hypothalamus
Normal corpus luteum function requires optimal follicu-
lar development in the follicular phase, especially follicle
stimulating hormone (FSH) stimulation, adequate lutein-
izing hormone (LH) surge during ovulation and continu-
ous tonic LH pulses during the luteal phase. In turn, the
normal luteal phase is characterized by an optimal hor-
monal environment and adequate endometrial secretory
transformation. As many factors contribute to a normal
corpus luteum function, any alteration might exert a dele-
terious effect on the final target, the endometrium, lead-Reproductive Biology and Endocrinology 2005, 3:54 http://www.rbej.com/content/3/1/54
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ing to embryo/endometrial asynchrony [5]. Luteal phase
insufficiency due to corpus luteum defects and LH sup-
pression is known to be associated with failure to achieve
and maintain pregnancy [194].
Effect on LH secretion
The lifespan and steroidogenic capacity of the human cor-
pus luteum is dependent on continuous tonic luteinizing
hormone secretion as well as healthy adequate gonado-
tropins surge. Feedback mechanisms from ovarian ster-
oids and GnRH pulses regulate LH secretion during the
luteal phase, but a number of autocrine and paracrine fac-
tors within the ovary might also play a role in controlling
corpus luteum function [5].
Effect on LH surge
It is obvious that during COH for ART, the prevention of
endogenous LH surge is mandatory to avoid the occur-
rence of premature LH surge as well as for timing of oocyte
retrieval.
However, during ovarian stimulation cycles in which no
pituitary suppression is used, there are data that suggest a
defective endogenous gonadotropins surge. The gonado-
tropins surge is an event crucial for final oocyte matura-
tion, ovulation, and subsequently for corpus luteum
function. The duration of the LH peak seems to be more
important than its amplitude for the induction of ovula-
tion [195]. Ovulation induction by hCG is not physiolog-
ical; the absence of an FSH surge, and the long duration of
LH activity associated with hCG action, would contribute
to some of the luteal phase abnormalities [196].
Messinis demonstrated that an attenuated LH surge is
obtained in normally cycling women during superovula-
tion induction with sequential clomiphene/hMG treat-
ment. The peak values and the duration of the LH surge to
have significant negative correlations with the plasma E2
levels, the number of follicles, and the total follicular fluid
volume aspirated at laparoscopy. This suggests that during
superovulation induction for IVF-ET, the endogenous LH
surge is attenuated by factors, which are related to the
degree of ovarian hyperstimulation [197].
As shown above, the induction of superovulation in
women with human gonadotropins may result in block-
age of the endogenous LH surge, but the reasons for this
are not known. A high number of small follicles have been
suggested to have a suppressive effect on both tonic and
mid-cycle gonadotropins secretion [198].
Effect of abnormal LH surge on nuclear maturation of the egg
A timely LH surge of adequate amplitude and sufficient
duration is important to bring about rapid and complex
cellular differentiation, resulting in cascades of tightly
coupled biochemical events, which initiate oocyte matu-
ration, ovulation, and corpus luteum formation [199]. It
is known that a midcycle LH surge of sufficiently high
amplitude and duration is important for both nuclear and
cytoplasmic maturation, which ensure the normal fertili-
zation and developing potential of oocytes [199]. For
PMSG-hyperstimulated rats, higher doses of hCG are
required to completely ovulate the expanded cohort of
preovulatory follicles [200].
Effect on LH tonic pulse during the luteal phase
Low luteal LH levels have been described after human
menopausal gonadotropins treatment6 and after GnRH-
agonist treatment or after GnRH-antagonist treatment.
These low, almost undetectable, luteal LH levels may not
be able to support corpus luteum. As a result, a shortened
luteal phase and low mid-luteal progesterone concentra-
tions have been described in cycles stimulated with the
association either of a GnRH agonist or a GnRH antago-
nist [195,196].
Supraphysiological progesterone serum concentrations
may also interfere with the pituitary's luteinizing hor-
mone secretion by disturbing the feedback control mech-
anisms and may result in a reduction of the LH serum
levels [195,196]. Progesterone modulates LH secretion
during the luteal phase by influencing the LH pulse ampli-
tude and pituitary release of LH [201]. A longer exposure
to progesterone or the combined action of estrogen and
progesterone decreases LH release [302]. As ovarian stim-
ulation results in supraphysiological steroid serum con-
centrations, these high steroid levels may adversely affect
LH secretion via a long-loop feedback mechanism. In
turn, disturbed LH secretion may induce a luteal-phase
defect with premature luteolysis, low progesterone levels
and shortened luteal phase. It might therefore be hypoth-
esized that deviation from the normal hormonal environ-
ment could be a prevalent effect of ovarian stimulation in
the luteal phase; despite the use of different stimulation
protocols [7]. This might be a possible explanation of the
observation that in natural cycle, luteal-phase length was
normal after GnRH-antagonist treatment [203]. However,
in GnRH-antagonist cycles and after minimal ovarian
stimulation, luteal-phase length was normal despite an
abnormal endocrine profile [204].
3.1.6 Other probable effects of supraphysiological estrogen levels
There are other less defined probable mechanisms
through which supraphysiological estrogen levels may
cause adverse effects on the outcome of infertility
treatment.
(A) Leptin-mediated effect
Recently, an important role for the leptin, the secretory
product of adipocytes, in reproductive medicine hasReproductive Biology and Endocrinology 2005, 3:54 http://www.rbej.com/content/3/1/54
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emerged and it is interesting to discuss in brief a possible
link between leptin, induction of ovulation and aro-
matase inhibitors.
Soon after its discovery in the early 1990s, it was recog-
nized that leptin played a significant role in reproduction,
providing a critical link between metabolic state and fer-
tility. It now appears that leptin may have an important
role in both normal ovarian physiology and pathophysi-
ology. Research has revealed that a minimum level of lep-
tin stimulation is required for maintenance of fertility in
animals and humans. Conversely, elevated leptin levels
may impair fertility [205].
Leptin is a secretory product of adipocytes that correlates
significantly with the body mass index with increased lev-
els in obese women [206]. It can influence reproduction
through central (on GnRH neural system) and peripheral
(on the ovary directly) mechanisms [205]. A positive cor-
relation has been found between leptin and BMI, as well
as between leptin and testosterone in women with poly-
cystic ovarian syndrome (PCOS) [207].
Numerous studies have shown that circulating leptin con-
centrations rise in parallel with E2 during ovarian stimula-
tion [208-213]. These changes are not likely to be a direct
action of FSH because FSH decreases as E2 and leptin rise
during natural cycles, and high FSH levels experienced
during ovarian stimulation simulate endogenous levels in
postmenopausal women, who have lower serum leptin
concentrations than premenopausal women [205]. Büt-
zow [206] found that the larger the increase in serum lep-
tin concentrations during FSH stimulation, the poorer the
ovarian response in terms of number of follicles and
retrieved oocytes. Moreover, higher serum leptin levels
were found in oligo- and amenorrheic women who failed
to respond to clomiphene therapy [214].
The effect of body weight on outcomes of assisted repro-
duction has been investigated. Fedorcsak [215] reported
that among patients who conceived, overweight patients
(BMI >25) had fewer oocytes retrieved, a higher miscar-
riage rate, and lower live birth rate. In a much larger retro-
spective study that included 8822 embryo transfer cycles,
the cumulative pregnancy rate progressively decreased as
BMI increased from <25 to >35 [216].
Higher follicular fluid leptin concentrations correlated
with lower intrafollicular oxygen concentration [pO2],
[217] a condition that negatively impacts oocyte develop-
mental competence [218] with a direct evidence of a rela-
tionship between leptin levels and ART outcome reported
by Mantzoros [219] who found significantly lower follic-
ular fluid leptin concentrations in women who became
pregnant within three cycles of IVF-ET or gamete intrafal-
lopian transfer (GIFT). More recently, a significant nega-
tive correlation between non-fasting serum leptin levels
measured at the beginning of FSH stimulation and preg-
nancy success in women undergoing first attempt IVF-ET
cycles was reported [220]. Moreover, as leptin receptors
are expressed in the human endometrium, [221] a role for
leptin in endometrial receptivity cannot be excluded.
These results imply that elevated leptin may be a key fac-
tor in obesity-related fertility problems, and conversely
that elevated leptin may negatively impact fertility inde-
pendently of body mass. Fewer good embryos and lower
implantation rate suggest that elevated leptin impairs
oocyte developmental competence and/or early cleavage
stage embryo development, possibly via direct actions on
the follicle [205].
E2 has been reported to increase leptin mRNA expression.
In human adipose tissue culture, E2 stimulated leptin
secretion in women but not in men [222]. In women, E2
was found to increase ob mRNA expression and leptin
release. Moreover, in adipose tissue of women, the estro-
gen precursors; testosterone and dehydroepiandrosterone
also induced an increase in leptin secretion, an effect that
was prevented by the aromatase inhibitor letrozole. More-
over, the stimulatory effect of E2 observed in women was
antagonized by the antiestrogen ICI182780 [223].
(B) Coagulation system
Estrogen has been pointed out as a pre-thrombotic factor.
It has long been established that both pregnancy and oral
contraceptive use have resulted in an increased level of
many coagulation parameters. Generally, this has been
thought to be a result of the estrogen component.
Although it has been well established that long-term
exposure to exogenous contraceptive steroids can have a
promoting influence on the potential for thrombosis in
women, it is less clear what role high levels of endogenous
steroids might play. Undefined coagulation abnormalities
were reported after hMG- and hCG-induced hyperstimu-
lation of the ovary in several women [224-227]. Kim et al.,
[225] noted a large increase in fibrinogen after hMG treat-
ment, accompanied by "significant increases" in the pro-
thrombin time. However, the statistically significant
activation of clotting factors occurring during controlled
ovarian hyperstimulation is usually not accompanied by
clinically significant coagulation disorders that may be
explained by either of the following: (1) the increased lev-
els of clotting activity were still "within normal limits";
(2) none of the patients had any conditions known to pre-
dispose to coagulopathies (history of coagulopathies,
phlebitis, damaged or compromised endothelial cells,
etc.); or (3) a combination of the two [226]. However,
such subtle coagulation disturbances may exert an adverse
effect on endometrial receptivity and the early develop-
ment of the placenta by affecting the microcirculation.Reproductive Biology and Endocrinology 2005, 3:54 http://www.rbej.com/content/3/1/54
Page 14 of 45
(page number not for citation purposes)
Two case reports were published of activated protein C-
resistant women who suffered a thrombotic event during
IVF-ET treatment [227,228]. Curvers [229] reported that
the only coagulation parameter that changed considera-
bly during IVF-ET treatment was the activated protein C
(APC). In their study, the authors observed that hyper-
stimulation, i.e. high estrogen levels, induce APC resist-
ance, and that under these conditions both the absolute
values and the changes in the APC and the estrogen levels
(hyperstimulation-baseline) correlate significantly. Prior
to that study, it was reported that high estrogen levels were
not associated with APC resistance [230,231]. However,
the APC resistance test used in these studies, which is
based on quantification of the effect of APC on the clot-
ting of plasma initiated via the intrinsic coagulation path-
way, is not very sensitive to changes in sex hormones
[232]. On the other hand, Curvers et al. [232], used an
assay that quantifies down-regulation of extrinsic coagula-
tion by APC that is particularly sensitive to hormonal
changes in women [232].
We think it is possible that the reported effect of ovarian
stimulation-associated supraphysiological levels of estro-
gen on the coagulation system, though being modest,
may contribute at least partially to the reduced implanta-
tion rate observed after assisted reproduction. This could
be due to an impact on the microcirculation in the
endometrium that could affect the early stages of the
implantation as well as the early development of the pla-
centa. However, more studies are needed to support this
hypothesis.
(C) Tubes and tubal transfer
Effect on the oviductal environment
Oviducts are biologically active, providing an environ-
ment that sustains and enhances fertilization during early
embryonic development as the embryo travels toward the
uterine cavity. Following superovulation, the fluid from
the oviduct seems to impair embryo development. Fur-
thermore, a stimulated oviductal environment has also
been shown to have a negative influence on the implanta-
tion capacity of mouse embryos [233].
Superovulation in the mouse was described as a model for intra-
uterine growth retardation
Superovulation is associated with a slower preimplanta-
tion embryo development, a later and impaired implanta-
tion and a prolonged gestation [234]. This suggests that
the oviductal milieu rather than the embryo quality are
responsible for the adverse effects observed after supero-
vulation. The stimulated oviductal environment impairs
the developmental capacity of embryos in comparison
with untreated pseudopregnant females. In-vitro culture is
also suboptimal but better than the stimulated oviductal
environment. However, a detrimental effect of hormonal
stimulation upon the oviductal environment has not yet
been demonstrated in the human. A possible potential
negative effect, however, is not contradicted by observa-
tions reporting a higher pregnancy rate after ovarian stim-
ulation and IUI compared to insemination alone [235]. In
the human, there are observations that GIFT results in
higher pregnancy rates in comparison with IVF-ET
[236,237]. It is difficult to interpret these data since the
embryos were exposed longer to the possible deleterious
stimulated oviductal environment-using GIFT whereas in
IVF-ET, possible "suboptimal" culture conditions as
opposed to in-vivo conditions were used. Since the intro-
duction of sequential culture media, incorporating amino
acids, vitamins and growth factors, the in-vitro culture of
embryos has been improved, resulting in implantation
rates of >50% per transferred blastocyst [238]. Confirma-
tion of these data in a trial would result in higher preg-
nancy rates than ever reported for GIFT [239].
Effect on the oviductal embryo transfer
Akira [240] has found that ovarian stimulation was asso-
ciated with accelerated oviductal embryo transport. The
authors have concluded that increased implantation fail-
ure in superovulated rats may result from the accelerated
embryo transport resulting from elevated E2/P ratio.
Accelerated oocyte/embryo transfer has been postulated
to be the mechanism behind which high doses of estrogen
work as postcoital emergency contraception as explained
later.
Post-coital contraception with estrogen
The achievement of very high levels of estrogen by admin-
istering exogenous estrogen has been suggested for post-
coital contraception as early as the 1960s, when high-dose
estrogen was identified as a highly effective emergency
contraceptive [241].
Greenwald [242] compared the response of the rabbit, rat,
mouse, hamster, and guinea pig, to a single post-coital
injection of E2 cyclopentylpropionate and showed that
post-coital treatment with estrogens caused either tube
locking of embryos or accelerated transport to the uterus.
Although other effects were also detected, the alteration in
oviductal transport accounted for the contraceptive effect.
Embryos that entered the uterus prematurely were
expelled whereas whose sojourn through the oviduct was
prolonged, degenerated.
Other investigators found that a single injection of E2 was
given at different times after coitus revealed that a wide
range of effectiveness can be achieved and suggested dif-
ferent mechanisms can account for the contraceptive
effect when the same steroid is given at different times
post-coitus [243,244]. Some believed the main target was
the endometrium where they observed stromal edema,Reproductive Biology and Endocrinology 2005, 3:54 http://www.rbej.com/content/3/1/54
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hemorrhage, and loss of decidua, all of which was consid-
ered unsuitable for implantation. Administering high
dose of estrogen in the preovulatory phase was found to
depress endometrial growth and angiogenesis through a
negative influence on the vascular endothelial growth fac-
tor [245]. This suggested that estrogens might interfere
with endometrial receptivity even if given before
ovulation.
Other mechanisms for the contraceptive effect of post-coi-
tal estrogen were found to operate in monkeys. If given in
the follicular phase, so as to advance the preovulatory
increment in plasma estrogen, they evoke a premature LH
surge that does not trigger ovulation and the formation of
a functional corpus luteum, and the spontaneous LH
surge is delayed or suppressed [246]. ER present in the
granulosa cells of antral and preovulatory follicles and in
luteal cells [247] allow for a diversity of effects in the
ovary. In rhesus monkey, supraphysiological doses of
estrogen given in the mid or late follicular phase induce
atresia or luteinization without rupture of the dominant
follicle, reduce the viability of granulosa cells, reduce the
synthesis of E2 and progesterone and are detrimental to
the oocyte [248].
Whatever the mechanism of action of high dose of estro-
gen for emergency contraception is, success in preventing
pregnancy provides another evidence of the toxic effect of
the supraphysiological estrogen levels fertilization,
implantation and early development of the embryo which
result in failure of achieving pregnancy.
[D] Effect on other factors involved in decidualization and early 
developing placenta
Paracrine factors
The importance of paracrine factors in mediating the cel-
lular and biochemical changes involved in embryo
implantation has been recognized. Many growth factors
and cytokines, such as inhibins and activins, whose
expression is generally limited to developmental and
pathological states, are produced by actively remodeling
endometrial cells, and play crucial roles in regulating
endometrial cell function. Example of these factors
includes the inhibin and activin family in the paracrine
regulation of endometrial receptivity, decidualization and
implantation. Estrogen is known to play an important
role in regulation of these factors as discussed by Jones
[249].
Role of Calcitonin
The peptide hormone calcitonin is currently being evalu-
ated as a potential marker of the fertile human
endometrium. In ovariectomized animals, it has been
shown that administration of estrogen together with pro-
gesterone inhibits progesterone-mediated calcitonin gene
induction.29 Such antagonistic interactions between estro-
gen and progesterone pathways have been documented
previously in breast and uterine cells. It has been pro-
posed that these phenomena reflect transcriptional cross
talk occurring between estrogen and PR co-expressed in
the same target tissue. A complex interplay of the two
ovarian hormones, progesterone and estrogen, in the uter-
ine milieu is believed to be critical for optimal calcitonin
gene expression [250,251].
3.2 Effect of the medications used for ovarian stimulation
3.2.1 Clomiphene citrate
In spite of the high ovulation rate with the use of clomi-
phene citrate (around 50–90%), the pregnancy rate is
much lower (around 20–40%) [252-254]. Moreover,
there is a higher than expected incidence of miscarriage in
conception cycles following clomiphene citrate treatment
[255]. Such discrepancy is believed to be due to the
peripheral antiestrogenic effect of clomiphene citrate, par-
ticularly at the level of the cervical mucus [256,257] and
endometrium, [258,259]. The persistence of the zu-iso-
mer of clomiphene citrate in the body due to its long half-
life (several weeks) and slow clearance adds to the accu-
mulation of the antiestrogenic effects over subsequent
cycles of administration [260,261]. There is also evidence
of a direct harmful effect of a high concentration of clomi-
phene citrate and its isomers on fertilization, and on early
mouse [262] and rabbit [263] embryo development. Such
effects, however, were not confirmed in other studies
[264,265]. There is still some controversy concerning a
direct effect on the quality of oocytes associated with clo-
miphene citrate treatment [266,267]. Decreased uterine
blood flow during the early luteal phase and the peri-
implantation stage is another explanation for the poor
outcome of clomiphene citrate treatment [268]. Other
investigators have suggested the presence of other unrec-
ognized infertility factors [269,270].
3.2.2 Gonadotropins
The existence of nongonadal gonadotropins (FSH, LH/
hCG) receptors was first suggested by Ziecik [270] who
conducted binding studies in the porcine uterus. Subse-
quently, nongonadal receptors were found in human
tissues, including endometrium, myometrium, fallopian
tube, umbilical cord, and brain, by using a variety of tech-
niques, including immunohistochemistry; Northern,
Western, and ligand blotting; and in situ hybridization
[271-274]. This would suggest a possible direct action of
the gonadotropins on the uterus and involvement in the
endometrial development, implantation and establish-
ment of pregnancy [275].
High concentrations of exogenous gonadotropins used
for hyperstimulation of folliculogenesis were shown to be
detrimental to oocyte and embryo development in manyReproductive Biology and Endocrinology 2005, 3:54 http://www.rbej.com/content/3/1/54
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animal species. This is believed to be due to the associated
supraphysiological E2 levels and other possible undeter-
mined factors associated with ovarian stimulation. How-
ever, a direct effect of gonadotropins cannot be ruled out.
It has been reported that early embryo loss due to supero-
vulation could be rescued by an injection of goat antise-
rum against PMSG [276].
Effect of gonadotropins on LH surge
It has been suggested that during ovarian stimulation, the
supraphysiological FSH levels that persist into the late fol-
licular phase, thereby overriding selection of the single
dominant follicle of the natural cycle, secretion of an
ovarian factor(s) blocks estrogen-induced LH surges
[277]. Accumulated evidence has indicated that the ova-
ries produce another non-steroidal substance, named
"gonadotropins surge-attenuating factor" (GnSAF), which
may play a role in the control of the midcycle luteinizing
hormone surge in women [278-281]. Although GnSAF
activity is present during superovulation induction, it is
still unclear whether this factor plays a physiological role
during the normal menstrual cycle. Treatment with FSH
initially attenuated the response of LH to GnRH via the
production of GnSAF from the ovaries, while around the
midfollicular phase, the rising concentrations of E2 were
able to overcome the attenuating effect of GnSAF and
increase pituitary sensitivity to GnRH. The increased pitu-
itary sensitivity in the midfollicular phase of the FSH-
treated cycles, however, was not further enhanced in the
late follicular phase despite the continuous rise in E2 val-
ues [282]. It is suggested that eventually GnSAF was able
to overcome the sensitizing effect of E2
Effect of gonadotropins on chromosomal development
A dose-response relationship between the PMSG dose and
the incidence of polyploidy in the CD-1 mouse has been
reported with the level of polyploidy rising from 2.9%
with 10 IU PMSG to 10.5% with 15 IU PMSG, in the zygot
stage. Both a disturbance at maturation division and an
error at fertilization were the cause of polyploidy [22].
Whether this is the direct effect of PMSG or the resultant
ovarian stimulation is not known.
3.2.3 GnRH analogues
GnRH plays a pivotal role in the control of female repro-
duction and is secreted by hypothalamic neurons in a pul-
satile way. It binds to specific receptors on pituitary
gonadotrophs, which is followed by the secretion of the
gonadotropins, LH and FSH, which regulate steroidogen-
esis and gametogenesis in the ovary [283].
GnRH analogues are able to suppress gonadotropins
release and, subsequently, gonadal function. This is the
basis for their clinical application in ovarian stimulation.
Several agonistic or antagonistic GnRH analogues have
been developed for this purpose [284].
Effect of GnRH analogues on ovarian steroidogenesis and corpus 
luteum function
GnRH receptors and GnRH receptor mRNA were found to
be expressed in human granulosa-luteal cells GnRH recep-
tors have been found in the luteinized human granulosa
cells, and a possible direct effect of GnRH on ovarian ster-
oidogenesis has been suggested [485,486].
Although there are many studies that investigated the pos-
sible direct effect of various GnRH agonists on ovarian
steroidogenesis and hence the corpus luteum, there is no
consensus of the effects in the human ovary. Also, there is
little information concerning the direct effect of GnRH
antagonists on ovarian steroidogenesis [487]. A few stud-
ies that looked at the effect of GnRH agonist treatments in
vivo on in vitro steroidogenesis by human luteinized
granulosa cells, found an impairment of progesterone
production [287-290]. Minaretzis [291] have reported on
the effect of the GnRH antagonist Nal-Glu compared with
GnRH agonist leuprolide acetate treatment of patients
undergoing controlled ovarian hyperstimulation. The
progesterone production in human luteinized granulosa
cells cultures was not different between the two groups.
Both GnRH antagonists had no effect on basal or hCG-
induced E2  or progesterone production by granulose
lutein cells, independent of whether the cells were
exposed to the compounds in vitro or in vivo. However,
an in-vitro study demonstrated an inhibitory effect of
GnRH antagonist on gonadal steroid secretion [292]. Pel-
licer and Miro who found that GnRH agonist exposure in
vivo may affect human luteinized granulosa cells function
in vitro. They compared the progesterone accumulation in
human luteinized granulosa cells cultures between
patients treated with clomiphene citrate/gonadotropins
and GnRH agonist/gonadotropins. Granulosa cells
obtained from patients treated with the GnRH agonist
had lower progesterone production than cells isolated
from women treated with clomiphene citrate/gonadotro-
pins [293]. However, Minaretzis compared the human
luteinized granulosa cells steroidogenesis in vitro from
Nal-Glu and leuprolide acetate-treated women
respectively. They reported that basal and gonadotropins-
stimulated progesterone secretion was similar in the two
treatment groups [291].
Weiss et al., found that in vivo treatment with triptorelin
or the two GnRH antagonists, cetrorelix and ganirelix; did
not have an effect on spontaneous or hCG-stimulated
steroidogenesis. The authors also performed in vitro treat-
ments with triptorelin, cetrorelix and ganirelix for up to
96 hours and did not find any effect of these treatments
on basal or hCG-stimulated steroid production [287].Reproductive Biology and Endocrinology 2005, 3:54 http://www.rbej.com/content/3/1/54
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In all prior reports, which studied the effect of GnRH ago-
nist treatment on ovarian steroidogenesis, only the effect
of hCG on progesterone secretion by human luteinized
granulose cells was investigated. Recently, we examined
the effect of two known physiologic stimuli of ovarian
steroidogenesis, hCG and insulin. We found that GnRH
agonist treatment affected both the basal and hCG-stimu-
lated progesterone production by human luteinized gran-
ulosa cells but the pattern of insulin-stimulated
progesterone secretion was not affected. Because insulin
and hCG may share common pathways beyond but not at
the level of receptor activation, we hypothesize that in-
vivo GnRH agonist might affect the expression and/or
activation of LH receptors. In our study, we found that
human luteinized granulosa cells from patients treated
with GnRH antagonist responded to hCG in a fashion
generally consistent with previously reported hCG-stimu-
lated human luteinized granulosa cells progesterone pro-
duction [294]. In addition, the basal progesterone
production and absolute levels of insulin-stimulated pro-
gesterone production were both significantly higher than
observed following GnRH agonist treatment. In contrast,
human luteinized granulosa cells previously exposed in
vivo to GnRH agonist had a blunted P response to hCG.
Our results, therefore, support the hypothesis that GnRH
agonists may have a direct negative effect on human ovar-
ian steroidogenesis by the corpus luteum and suggest that
luteal function may be less affected during IVF-ET cycles
when GnRH antagonist is used. However, in another
study, GnRH antagonist therapy in women undergoing
ovarian stimulation was found to be associated with a sig-
nificant effect on ovarian follicular steroidogenesis. The
authors found the mean follicular fluid E2 concentration
significantly lower in patients treated with GnRH antago-
nist than in those treated with GnRH agonist. However,
no significant differences were found between groups in
follicular fluid progesterone concentrations [295]. How-
ever, further studies are required to investigate the effect of
GnRH agonist and antagonist on gonadotropins receptors
and different enzymes involved in ovarian steroidogene-
sis by the corpus luteum.
Effect on LH secretion
Because pituitary LH secretion is dependent on GnRH
stimulation and feedback mechanisms from ovarian ster-
oids, any alteration may be deleterious. In cycles using
GnRH agonists for ovarian stimulation, a significant drop
in mid-luteal progesterone concentrations was observed,
consistent with corpus luteum insufficiency. Long-term
GnRH-agonist administration has been associated with a
profound desensitization of the pituitary cells. In fact,
studies on pituitary gonadotropins secretory capacity after
GnRH-agonist treatment have indicated that this remains
impaired for at least 14 days after the discontinuation of
the GnRH-agonist and for the whole length of the luteal
phase [296]. In a randomized trial, it was also demon-
strated that, despite the early cessation of the GnRH ago-
nist in the follicular phase, luteal-phase characteristics
were abnormal [297].
GnRH-antagonist treatment has been shown to be effec-
tive in blocking the LH surge. GnRH antagonists bind
competitively to pituitary GnRH receptors and cause an
immediate inhibition of gonadotropins release. In con-
trast to GnRH agonists, it was suggested that treatment
with GnRH antagonists might not adversely affect luteal
LH secretion, since the pituitary maintains its responsive-
ness to the endogenous GnRH stimulus [298]. A normal
luteal phase, in terms of duration and serum progesterone
concentrations, was observed in natural cycles in which
an antagonist was administered to prevent the LH surge
[299]. However, data on the luteal phase from unsupple-
mented cycles after antagonist administration are limited
as a result of the small number of patients involved and
are rather controversial. Four out of six patients had either
a shortened luteal phase or low progesterone concentra-
tions in cycles stimulated with HMG and the GnRH antag-
onist Cetrorelix and receiving no luteal-phase
supplementation. However, with or without luteal-phase
supplementation, luteal LH levels were low, indicating
that another mechanism might be involved [299,300].
3.2.4 Human chorionic gonadotropins
Supraphysiological steroid serum concentrations may
interfere with LH secretion via long-loop feedback, but,
additionally, the exogenously administered hCG might
amplify LH secretion arrest via a second short-loop nega-
tive feedback. Although in the monkeys such a negative
feedback exists [301] there is a debate in the literature
about its existence in humans, with some of the studies
supporting this hypothesis [302] and others not
[303,304]. Nevertheless, findings from in-vitro studies
further support this idea. GT1-7 neurons, which are mor-
phologically and functionally similar to GnRH neurons,
were found to contain LH/hCG receptors. In addition,
exogenously administered hCG was found to decrease the
expression of GnRH receptor gene in GT1-7 cells or GnRH
secretion in immortalized GnRH neurons [305].
4 Measure to improve treatment outcome after ovarian 
stimulation and assisted reproduction
Even if the results of reproductive medicine have
improved in terms of numbers of pregnancies, it is still
striking that it is necessary to use stimulation which some-
times leads to hyperstimulation and multiple pregnan-
cies, that embryo development in vitro is still limited, that
implantation only occurs for 15–20% of transferred
embryos and this ratio has not changed significantly
along the last 25 years. We still need to improve tech-
niques to gain pregnancy rates approaching 50% perReproductive Biology and Endocrinology 2005, 3:54 http://www.rbej.com/content/3/1/54
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embryo. During assisted reproduction technology inter-
ventions, controlled ovarian stimulation is used to obtain
several oocytes in attempts to increase the likelihood of
having at least one developmentally competent embryo
available for transfer. However, current techniques for
identifying the competent embryo[s] are by no means per-
fect. These limitations, coupled with pressures to maxi-
mize the chance of pregnancy, typically result in the
transfer of multiple embryos. Not surprisingly, this prac-
tice has resulted in an unacceptably high rate of multiple
pregnancies arising from IVF-ET. During the last few years,
concerted efforts have focused on reducing these rates by
restricting the number of embryos to transfer [306].
In order to fulfill this task, several approaches have been
suggested to improve the outcome of treatment after ovar-
ian stimulation and assisted reproduction. Table 3 sum-
marizes the different approaches including the two main
approaches tried so far i.e. optimizing ovarian stimulation
protocols and improving embryology techniques. A third
approach we suggest i.e. the use of aromatase inhibitors
constitutes the third and most recent approach.
We suggest a THIRD novel approach that we believe it
may carry a hope for improving the outcome of treatment
after ovarian stimulation and assisted reproduction. This
approach involves the use of aromatase inhibitors.
4.1 Modified ovarian stimulation protocols
4.1.1 Reducing the intensity of ovarian stimulation protocols
Different approaches have been suggested to improve the
treatment outcome during assisted reproduction by
reducing the intensity of ovarian stimulation that would
reduce the high estrogen levels [307]. These approaches
include no-stimulation (natural cycle IVF-ET), minimal
stimulation IVF-ET cycles, step-down protocols, FSH
coasting and in vitro maturation.
However, all these measures are associated with the major
drawback of affecting the main goal of ovarian
stimulation, which is the achievement of a suitable
number of embryos when a good number of oocytes
retrieved.
Natural cycle IVF-ET
The first IVF-ET treatment in the literature was a natural
cycle IVF-ET. Since then natural cycle IVF-ET has been
largely replaced by IVF-ET with ovarian stimulation. Nat-
ural cycle IVF-ET has several advantages including a close
to zero multiple pregnancy rate, and a zero risk of ovarian
hyperstimulation syndrome as well as being less time con-
suming, physically and emotionally less demanding for
patients, and cheaper than stimulated IVF-ET. However, it
seems to be less effective. Unfortunately, good quality ran-
domized controlled trials and formal cost-effectiveness
analyses are lacking. Pelinck reviewed 20 selected studies
that comprised a total of 1800 cycles of natural cycle IVF-
ET, resulting in 819 embryo transfers (45.5% per cycle)
and 129 ongoing pregnancies (7.2% per cycle and 15.8%
per embryo transfer). The authors concluded that: in spite
of being a low-risk, low-cost and patient-friendly proce-
dure, high cancellation rates because of premature LH rise
and premature ovulations hamper efficacy of natural cycle
IVF-ET and that a randomized controlled trial comparing
natural cycle IVF-ET with current standard treatment strat-
egies is warranted. [27].
The cumulative live birth rates after four cycles of treat-
ment was reported to be 32% which is comparable with
the value of 34% for women having conventional IVF-ET
treatment [308]. However, there is enough data on cumu-
lative live birth rates following conventional IVF-ET,
which is likely that current cumulative rates for IVF-ET will
be higher than previously reported.
In the implantation rate per embryo after natural cycle
IVF-ET was found quite acceptable up to 50%. Also, the
fertilization rate was found to be 100% for the oocytes
retrieved from the mature follicles (as reviewed by [27]
Pelinck). We believe that the significantly better oocyte
Table 3: Various approaches to improve treatment outcome 
after ovarian stimulation:
(1) Approaches involving ovarian stimulation protocols:
A: Reduce intensity of ovarian stimulation
- No stimulation: natural cycle
- Minimal stimulation
- Step-down protocol








(2) Improving embryology techniques
- Improving embryo culture conditions, selection and extending 
embryo culture (blastocyst transfer)
- Preimplantation genetic diagnosis
- In vitro maturation
- Micromanipulation including: ICSI, assisted hatching, mitochondrial 
injection and cytoplasmic and nuclear transfer.
(3) The use of aromatase inhibitors for
- Improving implantation rates
- Reducing FSH dose required for ovarian stimulation:
- Other possible benefits:
* Improving response to FSH stimulation in poor responders
* Preventing premature endogenous gonadotropin surge
* Reducing the risk of severe ovarian hyperstimulationReproductive Biology and Endocrinology 2005, 3:54 http://www.rbej.com/content/3/1/54
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quality (100% fertilization rate) as well as better implan-
tation rate (about 50%), reflect clearly the value of avoid-
ing the deleterious effects of ovarian stimulation on the
treatment outcome. Moreover, there is an important point
to mention regarding the success rates of natural IVF-ET
cycles, which is the bias in selecting patients who under-
went natural IVF-ET cycles. Many studies included
patients with unfavorable outcome such as poor respond-
ers, old age and repeated IVF-ET failures.
Minimal stimulation IVF-ET
Minimal stimulation for IVF-ET that is less expensive than
full stimulation and minimizes monitoring and patient
discomfort has been described for almost 10 years and
found to be associated with acceptable pregnancy rates
and was suggested as an attractive alternative to select
patients undergoing IVF-ET [309]. This protocol involves
the use of CC plus FSH alone or in conjunction with
GnRH antagonist to prevent premature LH surge [310]. It
is expected that the minimal-stimulation regimens pro-
duce fewer oocytes, fewer embryos available after fertiliza-
tion, and fewer excess embryos available for
cryopreservation. This leads to the main drawback of the
minimal-stimulation regimen, which is the lower total
reproductive potential (pregnancies resulting from fresh
and frozen-thawed embryos resulting from a single stim-
ulation cycle) [311].
FSH step-down and coasting protocols
Other measures have been tried by decreasing the FSH
dose (step down protocol) to improve endometrial recep-
tivity. With the use of a step-down regimen with FSH in
high responders, uterine receptivity was believed to
improve secondary to lowering E2 levels during the preim-
plantation period [312].
Coasting or withholding FSH injection for a period of
time has been suggested in patients at substantial risk for
the development of severe hyperstimulation syndrome.
Coasting in a studied subset of IVF-ET patients did not
adversely affect cycle outcome parameters when it was not
prolonged [313].
4.1.2 Application of new medications for ovarian stimulation
The ongoing development of more effective and safer
pharmacological compounds is driving fundamental
changes in medicine [314]. Along the last decade several
new medications have been developed for application in
ovarian stimulation and assisted reproduction including
medications prepared by the new recombinant technol-
ogy [recombinant FSH and LH] and GnRH antagonists as
well as other medications.
Recombinant FSH
The introduction of recombinant FSH into the clinical
management of patients suffering from infertility appears
to be associated with several treatment benefits when
compared with urinary human menopausal
gonadotropins
The fact that rFSH preparations have batch-to-batch con-
sistency, are free from urinary protein contaminants and
have the potential to be produced in limitless quantities is
advantageous. The question whether newer, more pure
FSH products are beneficial from the clinical perspective,
has not been settled beyond reasonable doubt. The price
of rFSH has been reported to be three times as high as the
price of the former FSH preparations [315].
Although both FSH and LH are required for normal follic-
ular growth and maturation, the precise role of LH is at
present still uncertain. Since it was shown in the late
1980s that too high a concentration of LH might have a
negative effect on fertilization and embryo quality, the
idea arose that pure FSH preparations might be superior
to hMG preparations for patients with endogenous LH
production [316]. This hypothesis was tested in several
clinical trials comparing uFSH with hMG with respect to
pregnancy rates per IVF-ET treatment cycle. Statistical sig-
nificance was not reached in any of these individual stud-
ies [316,317]. However, in 1995 a meta-analysis by Daya
was published, which included eight studies and demon-
strated a significant difference in favor of uFSH [316]. A
few years later this finding was contradicted by a meta-
analysis by Agrawal who argued that meta-analyses
should take into account the different pituitary desensiti-
zation protocols used [318]. When pooling together 11
trials with the most commonly used GnRH agonist
protocol [the long protocol], the overall odds ratio for
comparing FSH and HMG was not significant. Although
this meta-analysis was criticized on the issue of study
selection bias, re-analysis following the inclusion and
exclusion of selected studies did not change the overall
results of the study [316,318,319].
The question whether rFSH also leads to more clinical
pregnancies per IVF-ET cycle has been addressed by sev-
eral clinical trials, none of which reached statistical signif-
icance. However, two meta-analyses pooling together the
results of several trials did show significant treatment
effects in favor of rFSH [320,321]. The interpretation of
these meta-analyses is still debated, since they compare
two types of rFSH (the alpha and beta variant), as well as
different types of urinary FSH (uFSH and uFSH-HP, and in
Out's meta-analysis one study with HMG was also
included). In Daya's analysis, which received Cochrane
status, an absolute increase in pregnancy rates of 3.7%Reproductive Biology and Endocrinology 2005, 3:54 http://www.rbej.com/content/3/1/54
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(95% confidence interval [CI] 0.5–6.9%) was demon-
strated comparing rFSH with uFSH/uFSH-HP.
Data on the third possible comparison, between rFSH and
hMG, are scarce. The studies that have been conducted so
far found no statistically significant differences with
respect to ongoing pregnancy rates [322-324]. The evi-
dence available at this time, comparing the different FSH
containing gonadotropins preparations, concerns their
usage in IVF-ET. However, almost half of all gonadotro-
pins are used in other settings, such as IUI. Very little data
are available comparing the preparations for this indica-
tion. With respect to adverse effects of exogenous FSH
administration, no significant differences have been
found between products. The main risk associated with
the use of FSH containing gonadotropins products is the
development of the ovarian hyperstimulation syndrome
(OHSS). The incidence of OHSS does not differ between
products [321-324].
Recombinant LH
hCG has been used as a surrogate LH surge because of the
degree of homology between the two hormones. The
major differences between the two hormones include the
sequence of the β-subunit, the regulation of the secretion
of the two hormones, and the pharmacokinetics of clear-
ance of hCG as opposed to LH [325,326].
hCG has a slower plasma metabolic clearance, which con-
sists of a rapid phase in the first 5–9 h following IM
administration and a slower phase in the 1–1.3 days after
administration. After 36 h, the calculated half-life of hCG
was 2.32 days, as compared with LH, for which estimates
have ranged from 1 h [326] to 3–5 h [327,328]. By day 10
after administration, less than 10% of the originally
administered hCG was measurable [329]. However, the
long serum half-life of hCG is likely to be an undesirable
characteristic in clinical practice.
Until recently, there was no other biologic preparation
that was as effective as hCG in triggering the final stage of
ovulation. Recent developments using genetic engineer-
ing technologies and posttranscriptional biosynthesis
have led to the production of rhLH, which has been avail-
able for use in clinical trials for several years [330]. The
rhLH produced in vitro is purified and further formulated
to yield a pharmaceutical preparation with very high spe-
cific immunoactivity and bioactivity. A crossover pharma-
cokinetic study has been performed in nonhuman
primates to assess and compare pituitary, urinary, and
rhLH [331]. After intravenous administration of pituitary
and urinary-derived LH, and rhLH, mean concentration-
time curves were parallel. The mean areas under the curve
(AUC) for concentration by time after dose curves were
similar, after correction for immunologic differences in
dose. The mean clearance estimates and volume of distri-
bution at steady state, distribution, and terminal half-lives
were similar for all three types of LH. Furthermore, the
results of studies in human volunteers show that rhLH
and urinary-derived hLH have similar pharmacokinetic
characteristics; both preparations presented an iv distribu-
tion half-life of 1.2 h and a terminal half-life of 10 h
[332,333]. rhLH total body clearance was 2 L/h, with less
than 5% of the dose being excreted by the kidneys. The
steady state volume of distribution was approximately 8 L
[332]. Furthermore, it has been demonstrated that co-
administration of rhLH and rhFSH (follitropin α) does
not modify their respective pharmacokinetic characteris-
tics [332]. Finally, low doses of rhLH have been shown to
promote ovarian steroidogenesis when follicular growth
is induced with rhFSH in hypogonadotropic hypogonadal
women [334].
The results show that a single dose of rhLH is effective in
inducing final follicular maturation and early
luteinization in IVF-ET and embryo transfer patients and
is comparable with 5,000 IU u-hCG. A single dose of rhLH
results in a highly significant reduction in OHSS com-
pared with hCG. The dose of rhLH giving the highest effi-
cacy to safety ratio was between 15,000 and 30,000 IU.
This study has shown that the incidence of OHSS is signif-
icantly smaller when using a single dose of rhLH for
induction of final maturation of follicles and oocytes in
women treated for IVF-ET, compared with the use of
5,000 IU u-hCG or two doses of rhLH [335].
Chandrasekher [336] compared rhLH with u-hCG and
pituitary hLH as an ovulatory stimulus in rhesus monkeys
before IVF-ET. These investigators found that a single
injection of 2,500 IU rhLH was as effective as 1,000 IU u-
hCG in inducing oocyte maturation, oocyte fertilizability,
and luteinization of granulosa cells. The data suggested
that using a conversion factor of 2.5, a dose of 12,500 IU
rhLH would be as effective as 5,000 IU u-hCG in humans.
Another study (unpublished data) looked at the sponta-
neous LH surges in seven healthy female volunteers with
normal menstrual cycles after a single injection of either
250  µg GnRH-agonist (buserelin) or 5,000 IU u-hCG
administered when the dominant follicle reached a diam-
eter of 17 mm. It was found that the mean Cmax of the
spontaneous LH surge was 47 IU/L (95% CI, 28–65 IU/L)
and the mean AUC was 1,019 IU h/L (95% CI, 718–1,320
IU h/L). Using rhLH pharmacokinetic characteristics
defined in Phase I studies [332,333], it was calculated
that, to obtain a Cmax and an AUC larger than the corre-
sponding mean values observed in spontaneous surges in
95% of cases, single sc injections of between 14,000 IU
and 25,000 IU rhLH should be used.Reproductive Biology and Endocrinology 2005, 3:54 http://www.rbej.com/content/3/1/54
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GnRH antagonists
GnRH antagonists do not induce an initial stimulation of
gonadotropins release, but cause an immediate and rapid,
reversible suppression of gonadotropins secretion. The
principal mechanism of action of GnRH antagonists is
competitive receptor occupancy of GnRH-r [337].
GnRH antagonists have been introduced clinically to pre-
vent premature endogenous LH surge to replace the
GnRH agonists that require time for a state of desensitiza-
tion to be reached and, to start with, LH secretion actually
increases (flare-up). With GnRH antagonists, immediate
blockade of pituitary gonadotropins secretion when pre-
mature luteinization during IVF-ET stimulation is immi-
nent seemed an obvious approach. Several studies of dose
and treatment schedules have been done, [338,339] and
two general approaches have emerged. The first is a single
subcutaneous injection of a large dose on about the eighth
day of stimulation with gonadotropins. The alternative is
multiple (five or six daily) injections of a small dose from
about day 6 of stimulation until the day that hCG for final
oocyte maturation is given.
The next step in the development of GnRH antagonists
use was to establish whether a GnRH antagonist is at least
as effective as a GnRH agonist as the established reference
medication testing the regimen of repeated antagonist
injections [340,341] or the regimen of a single-dose regi-
men [342].
With repeated injections, treatment with gonadotropins
was found to be shortened by 1–2 days with slightly fewer
follicles at the time of hCG injection so the number of
recovered oocytes tends to be lower. No significant differ-
ence was found with respect to percentages of metaphase
II oocytes, fertilization rates, and number of good quality
embryos [340,341].
Pregnancy rates were high in both groups in all four stud-
ies but in every one the rate was lower in the antagonist
group. A meta-analysis of the five randomized trials,
showed an overall significantly lower rate of pregnancy of
5%. This meta-analysis unfortunately included the study
that compared a single-dose analogue regimen with dif-
ferent gonadotropins starting dose as an additional varia-
ble [342]. It has been suggested that the larger numbers of
oocytes and embryos with agonists allow better selection
[343], although the numbers of good quality embryos do
not seem to be different. A direct adverse effect on the
embryo cannot yet be ruled out but is not likely.
Antagonist blockade allows immediate reversal of pitui-
tary gonadotropins secretion. This means that in IVF-ET
ovulatory ripening can be triggered via endogenous gona-
dotropins by using a GnRH agonist [344] with the
advantage of prevention of ovarian hyperstimulation syn-
drome, which is thought to result at least in part from the
prolonged LH effect of hCG [345]. Finally, the use of
GnRH antagonist blockade of premature luteinization can
be used in IVF-ET with very low or without any hormonal
stimulation, lower risk of overstimulation, and simplifica-
tion of the procedure [346].
A possible disadvantage of an antagonist in IVF-ET is its
narrow therapeutic range with the currently advised doses
for repeated injections. Patient compliance needs to be
high because there is a risk of premature LH secretion if an
injection is missed [337].
Another disadvantage is the unpredictable timing of the
start of the IVF-ET procedure, which begins with the
administration of FSH on day 3 of the woman's cycle and
so depends on how regular her menstruation is. This
problem may be solved by pretreatment with an oral con-
traceptive [335].
4.1.3 Use of adjuvant medication during ovarian stimulation
Insulin sensitizers
The independent effect of insulin resistance on infertility
treatment in PCOS is not well defined. Regardless of body
weight, insulin-resistant PCOS women need higher gona-
dotropins doses during ovarian stimulation, and insulin
resistance is also associated with a risk of multifollicular
development and high cancellation rate [347]. Hyperin-
sulinemic PCOS women are more likely to produce lower
quality oocytes that exhibit low fertilization rates after
IVF-ET in association with lower implantation rates [348].
Improving insulin resistance with exercise, low-calorie
diet and insulin-lowering drugs such as metformin, trogl-
itazone and acarbose decrease insulin levels, correct the
endocrine abnormalities induced by obesity and insulin
resistance which may improve the outcome of infertility
treatment [349-351]. This leads to the assumption that co-
treatment with insulin-lowering drugs or weight reduc-
tion before and during down-regulation and ovarian
stimulation.
Some studies did not find deleterious of insulin resistance
on ovarian stimulation [352]. Metformin treatment has
been reported to increase the number of mature oocytes
retrieved from women with PCOS undergoing gonadotro-
pins-stimulated IVF-ET and ICSI. A low dose of metformin
of 500 mg twice daily was started on day 1 of the cycle
prior to leuprolide acetate suppression, and continued to
the day of the pregnancy test. Metformin treatment signif-
icantly increased the number of mature oocytes, fertiliza-
tion rates, and number of embryos produced, but did not
alter the total number of oocytes or peak E2 levels [353].Reproductive Biology and Endocrinology 2005, 3:54 http://www.rbej.com/content/3/1/54
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Later, the same authors reported that metformin therapy
improves ovarian stimulation and IVF-ET outcomes in
coasted patients with clomiphene-resistant PCOS [354].
No further published reports to date have examined this
issue.
Corticosteroids
Successful use of corticosteroids in treatment of anovula-
tory infertility has been reported [355,356]. Later corticos-
teroids were used as adjuvant therapy together with
clomiphene citrate or gonadotropins in ovulation induc-
tion. The theoretical basis for this application has not
been fully elucidated, but it has been postulated that cor-
ticosteroid treatment could improve ovulation through
reduced influence of the adrenal androgens on follicular
development [357]. There have been reports on improved
ovulation and pregnancy rates with adjuvant corticoster-
oid treatment in anovulatory women with elevated andro-
gens or androgens within the higher range [358,359], as
well as in normoandrogenic women [360]. Adding dex-
amethasone to gonadotropins in ovulation induction in
women with normal serum concentrations of gonadotro-
pins, androgens, and prolactin did not give an improved
outcome in other studies [361].
Corticosteroids have also been used as adjuvant therapy
in IVF-ET treatment. In 1986, Kemeter and Feichtinger
[362] reported a significantly better pregnancy rate in a
group of women with various infertility causes, except
cycle abnormalities, undergoing IVF-ET with adjuvant
prednisolone treatment, as compared to a group of
women without adjuvant prednisolone. They stated that
prednisolone would improve follicle maturation and
thereby improve the pregnancy rate. In contrast, others
[363] did not see any beneficial effects of adjuvant dexam-
ethasone in a group of women with serum DHEA-S >2.5
µg/ml [6510 nmol/l] undergoing IVF-ET treatment, nei-
ther did Bider [361], in a group of women with tubal fac-
tor infertility after addition of dexamethasone.
In the above-mentioned study by Lobo [357], decreased
serum concentrations of testosterone, unbound testoster-
one, and DHEA-S were noted after dexamethasone and
clomiphene administration. In women who ovulated, tes-
tosterone and unbound testosterone increased again
when clomiphene was added despite the continuation of
dexamethasone. Decreased serum concentrations of
DHEA-S and testosterone after ovarian stimulation with
clomiphene citrate and human menopausal gonadotro-
pins (HMG) and adjuvant prednisolone have been
reported [362]. The other studies did not report data on
androgen concentrations after glucocorticoid treatment.
The present prospective, randomized, placebo-controlled
study was performed to find out if adrenal suppression
with prednisolone during ovarian stimulation before IVF-
ET in a group of women with PCOS resulted in any
changes in serum and follicular-fluid androgens. Clinical
outcome variables, such as embryo quality, implantation
rate, and clinical pregnancy rate were also noted.
Fridstrom [364] have reported that adjuvant glucocorti-
coids in ovarian stimulation before IVF-ET did not
decrease the concentrations of adrenal androgens in
serum and follicular fluid in PCOS. However, whether
there were beneficial effects on ovum quality or implanta-
tion rate could not conclusively be determined in their
study due to the small number of patients.
The addition of corticosteroids to ovarian stimulation
protocols for assisted reproduction has been suggested in
cases of recurrent pregnancy loss [365].
Progesterone antagonists: Receptor antagonist onapristone and 
mifeprisotone
Krusche found that after ovarian stimulation, the PR
antagonist onapristone retarded endometrial
transformation in the rabbit model. The authors con-
cluded that since ovarian stimulation, used in human IVF-
ET therapy, is frequently reported to cause an advance-
ment of post-ovulatory endometrial development, a ther-
apeutic application of PR antagonists to slow down such
advanced endometrial transformation was suggested.
Eventually, this modulation of advanced endometrial
development may improve implantation rates [366].
4.2 Improving embryology techniques
Improving embryo techniques is a very important
approach to improve the outcome of assisted reproduc-
tion treatment. This includes, improving culture condi-
tions and extended culture till the blastocyst stage as well
as improving the accuracy for selecting viable embryos for
transfer. Another strategy employs pre-implantation
genetic diagnosis (PGD). In addition there are other strat-
egies to improve the embryo quality including oocyte
donation and micromanipulation techniques (assisted
hatching, and cytoplasmic and mitochondrial transfer)
[367].
4.2.1 Improving embryo culture condition, selection and extended 
embryo culture (blastocyst transfer)
Over the past decade there has been considerable interest
in optimizing culture media for supporting human
embryos including reducing glucose concentrations
[368], adding amino acids [369] and supplementing
media with growth factors [370]. However, there have
been no large prospective randomized studies on the
effects of culture media on outcome after IVF-ET, apart
from one, which reported that although glucose-free
medium improved embryo quality, pregnancy rates were
not increased [371]. All these improvements as well as theReproductive Biology and Endocrinology 2005, 3:54 http://www.rbej.com/content/3/1/54
Page 23 of 45
(page number not for citation purposes)
growing data on the composition of human female repro-
ductive tract fluids and from embryo physiology studies
has led to the proposition that extended embryo culture
should take place till the blastocyst stage in more than a
single medium formulation [372]. To this end, sequential
media have been developed, tested extensively on animal
models and subsequently used clinically [373].
One approach to increasing pregnancy rates is to improve
the selection of viable embryos. Embryos are selected on
the basis of morphology and rate of development, and the
fastest developing embryos of the best morphology are
selected for transfer. Although there is some correlation
between morphology and blastocyst formation [374] and
implantation [375], selection on the basis of morphology
and rate of development remains an unsatisfactory and
imprecise method of selecting viable embryos. It is impos-
sible to identify visually with certainty, which embryos at
early cleavage stages will subsequently arrest. One
approach to improve the selection is the extended culture
of the embryos to the blastocyst stage and transfer them
on day 5 or 6, allowing the identification of developing
embryos and the transfer of blastocysts, which are syn-
chronous with the endometrium development, rather
than cleavage stage embryos. It had been hoped also that,
during extended culture, the chromosomally abnormal
embryos so common at early cleavage stages [376] would
arrest and fail to complete preimplantation development.
However, although few human blastocysts have total
chromosomal abnormality, a large number of blastocysts
have various proportions of abnormal cells and are
mosaic [377].
However, although many clinics have experienced
increased success with extended culture, others have
reported no benefit. So, it would be unwise to suggest that
blastocyst culture and transfer represents a panacea for all
clinics and all patients. On the contrary, transferring early
stage embryos (zygot intrafallopian transfer) may help in
repeated implantation failure rather than blastocyst trans-
fer. [378].
4.2.2 Preimplantation genetic diagnosis
Preimplantation genetic diagnosis (PGD) allows the diag-
nosis of a genetic disorder in an embryo before its implan-
tation in the uterus. PGD involves the removal of one or
two blastomeres from an eight-cell stage embryo after IVF-
ET, analysis of the blastomeres using fluorescent in situ-
hybridization (FISH) or PCR, and identifying affected
embryos. As only unaffected embryos are transferred back
to the uterus after PGD, termination can be avoided. PGD
is of benefit to couples at risk of passing on a genetic dis-
ease to their offspring as well as for couples with repeated
unexplained IVF-ET failures. The transfer of unaffected
embryos is believed to enhance the success rate of IVF-ET.
Unfortunately, a large number of oocytes need to be
retrieved for a successful PGD cycle, as not all will fertilize,
cleave, undergo successful biopsy and be identified as
suitable for transfer. Although most embryos (96%) sur-
vive biopsy, the pregnancy rates after transfer of biopsied
embryos (16% per treatment cycle) [377] are less than
those after conventional IVF-ET (23% per cycle) [379].
However, PGD is still in its early developmental stages
[14].
4.2.3 In-Vitro Maturation of Oocytes
Immature oocytes can be aspirated from small follicles of
> 2 mm in diameter. Resumption of meiosis in fully-
grown oocytes, germinal vesicle breakdown, extrusion of
the first polar body and acquisition of the ability to be fer-
tilized may all occur during in vitro maturation (IVM).
Although the first human birth after IVM was achieved 20
years ago [380], a few cases have been reported subse-
quently, including births after the aspiration and IVM of
oocytes retrieved from women who have natural or par-
tially stimulated cycles [381] and women with PCOS
[382]. When oocytes are removed from small antral folli-
cles and placed in culture, approximately 60% will have
undergone nuclear maturation within 48 h. After expo-
sure to spermatozoa, about 40% of oocytes will undergo
normal fertilization, exhibiting two pronuclei and extrud-
ing the second polar body. Between 20 and 25% of ferti-
lized oocytes will undergo cleavage [383]. However,
pregnancy rates after the transfer of such embryos have
been extremely low (1–2%) and most embryos arrest
between the four- and eight-cell stages with only few
encouraging results [384]. Several factors may influence
the fertilization, cleavage, blastocyst and pregnancy rates
achieved after IVM, including the hormonal environment
in vivo or in vitro and the composition of the culture
medium [385]. Further research in these areas will lead to
greater understanding of oocyte maturation and should
result in improved implantation and pregnancy rates [14].
4.2.4 Micromanipulation techniques
Intracytoplasmic sperm injection (ICSI)
The use of small numbers of spermatozoa during IVF-ET
results in fertilization failure. In these cases, it is possible
to inject a single spermatozoon into the ooplasm of a
mature metaphase II oocyte, a procedure known as ICSI.
The first successful pregnancies were in the early 1990s
[10]. Since then, the technique has become a widely
accepted treatment for couples with severe male factor
infertility. Extending the indication of ICSI to include
non-male factor infertility has been suggested to improve
the fertilization and pregnancy rates. However, several
studies have not supported the benefit of ICSI over con-
ventional IVF-ET in improving the treatment outcome for
non-male factor indications with growing consensusReproductive Biology and Endocrinology 2005, 3:54 http://www.rbej.com/content/3/1/54
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against applying ICSI for all cases undergoing IVF-ET
[386-389].
Assisted hatching
To help embryos hatching from their zona pellucida dur-
ing blastocyst expansion, different types of assisted hatch-
ing have been developed, including mechanical partial
zona dissection or zona drilling, chemical zona drilling
with acidic Tyrode's solution, and the laser technique
[176]. However, there is controversy about the benefit of
assisted hatching on the improvement of the implanta-
tion rate and pregnancy rate. Some investigators agreed as
to the benefit of assisted hatching in women with
advanced age, in women with repeated IVF-ET failure, and
in the general population [177,178].
Mitochondrial injection and cytoplasm, and nuclear transfer
Van Blerkom suggested that the developmental compe-
tence of mouse and human early embryos is related to the
metabolic capacity of the mitochondria [144]. Deletions
and mutations in oocyte mtDNA may lead to mitochon-
drial dysfunction, influencing energy production and
apoptosis in oocytes and early embryos, resulting in aber-
rant chromosomal segregation or developmental arrest
[144]. In mice, cytoplasmic transfer from young to old
oocytes improved older oocytes quality [390].
Cytoplasmic transfer from metaphase II donor oocytes to
mature recipient oocytes from women with recurrent IVF-
ET failure has been carried out in an attempt to restore
normal growth in developmentally compromised oocytes
and embryos [391].
Nuclear transfer has also been proposed for the treatment
of mitochondrial disease [392] whereby a karyoblast con-
taining metaphase II chromosomes from women with
repeated failures of embryo development due to defective
oocyte cytoplasm is fused to enucleated donor oocytes.
The increased cost and complexity as well as the invasive-
ness of the procedure with the decreased implantation
rates all make these procedures far from being applied
routinely to improve the treatment outcome after assisted
reproduction. Only selected cases might be expected to
benefit from these newly developing techniques. It should
be noted that currently in the United States, performance
of cytoplasmic or nuclear transfer in humans can only be
conducted following approval of the protocol by the FDA.
PART TWO
1. Aromatase inhibition to improve outcome of treatment 
after ovarian stimulation
1.1 Introduction
We hypothesize that aromatase inhibitors can be used to
improve the treatment outcome after ovarian stimulation
either alone, or in combination with IUI and assisted
reproductive technology. The use of aromatase inhibitors
during ovarian stimulation may have several benefits
including: (1) The enhancement of implantation by low-
ering the supraphysiological levels of estrogen attained
during ovarian hyperstimulation that is believed to
adversely affect the development of the endometrium,
oocytes and embryo, as well as other possible targets. (2)
Reducing gonadotropins dose required for achievement
of optimum ovarian stimulation. This would reduce pos-
sible deleterious direct effects of exogenous gonadotro-
pins injection in addition to reducing the cost of
treatment. (3) Other possible benefits such as improve-
ment of ovarian response to FSH stimulation in poor
responders, and prevention of premature endogenous
gonadotropin surge, as well as lower risk of severe ovarian
hyperstimulation syndrome.
The improvement in implantation, as well as the reduced
cost of treatment by decreasing the gonadotropins dose
required for ovarian hyperstimulation would encourage
the policy of transferring one embryo to minimize the risk
of multiple gestation. This would have a tremendous
economic impact on the practice of assisted reproduction,
as well as cost of health care for multiple gestation
worldwide.
1.2 Outline of the use of aromatase inhibitors for ovarian stimulation
In the following section, we present brief outline on the
aromatase enzyme, estrogen biosynthesis and the devel-
opment of aromatase inhibitors followed by a summary
of the available data concerning the use of aromatase
inhibitors for ovarian stimulation.
The aromatase enzyme
Aromatase is a microsomal member of the cytochrome
P450 hemoprotein-containing enzyme complex super-
family (P450 arom, the product of the CYP19 gene) that
catalyzes the rate-limiting step in the production of estro-
gens, that is, the conversion of androstenedione and tes-
tosterone via three hydroxylation steps to estrone and E2
respectively [393]. Aromatase activity is present in many
tissues, such as ovaries, brain, adipose tissue, muscle,
liver, breast tissue, and in malignant breast tumors. The
main sources of circulating estrogens are the ovaries in
Table 4: Different classes of aromatase inhibitors:
Generation Non-Steroidal Steroidal
First Generation Aminogltethimide
Second Generation Rogletimide Formestane
Fadrozole
Third Generation Anastrozole Exemestane
Letrozole
VorozoleReproductive Biology and Endocrinology 2005, 3:54 http://www.rbej.com/content/3/1/54
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premenopausal women and adipose tissue in postmeno-
pausal women [394,395].
The development of aromatase inhibitors
Aromatase is a good target for selective inhibition because
estrogen production is a terminal step in the biosynthetic
sequence. Several aromatase inhibitors have been utilized
in clinical studies over the last 20 years. The most success-
ful, third generation aromatase inhibitors are licensed for
breast cancer treatment [396]. Aromatase inhibitors have
been classified in a number of different ways, including
first-, second-, and third-generation; steroidal and non-
steroidal; reversible (ionic binding), and irreversible (sui-
cide inhibitor, covalent binding) [397]. Table 4 lists the
different classes of aromatase inhibitors.
Steroidal aromatase inhibitors are androstenedione ana-
logues that act as a false substrate and bind irreversibly to
the androgen-binding site of the enzyme [398]. Non-ster-
oidal aromatase inhibitors exert their function through
binding to the heme moiety of the cytochrome P450
enzyme [399]. The first of these inhibitors to be used clin-
ically was aminoglutethimide, which induces a medical
adrenalectomy by inhibiting many other enzymes
involved in steroid biosynthesis [400]. Although
aminoglutethimide is an effective hormonal agent in
postmenopausal breast cancer, its use is complicated by
the need for concurrent corticosteroid replacement, in
addition to side effects like lethargy, rashes, nausea and
fever that result in 8–15% of patients stopping treatment
[401,402]. The lack of specificity and unfavorable toxicity
profile of aminoglutethimide led to the search for more
specific aromatase inhibitors. In addition, the above men-
tioned aromatase inhibitors were not able to completely
inhibit aromatase activity in premenopausal patients.
Third generation aromatase inhibitors
The third-generation anti-aromatase agents commercially
available include two non-steroidal preparations, anastro-
zole and letrozole, and a steroidal agent, exemestane.
Anastrozole and letrozole are often referred to as aro-
matase inhibitors, whereas exemestane is called an aro-
matase inactivator [403,404]. Anastrozole, ZN 1033,
(Arimidex®) and letrozole, CGS 20267, (Femara®) are
selective aromatase inhibitors, available for clinical use in
North America, Europe and other parts of the world for
treatment of postmenopausal breast cancer. These triazole
(antifungal) derivatives are reversible, competitive aro-
matase inhibitors, which are highly potent and selective.
At doses of 1–5 mg/day, they inhibit estrogen levels by
97% to >99% resulting in estrogen concentrations below
detection by most sensitive immunoassays. Table 5 shows
the relative potencies of different aromatase inhibitors.
Aromatase inhibitors are completely absorbed after oral
administration, with mean terminal half-life (t1/2) of
approximately 45 hours (range, 30–60 hours). They are
cleared from the systemic circulation mainly by the liver.
Gastrointestinal disturbances account for most of the
adverse events, although these have seldom limited ther-
apy. Other adverse effects are asthenia, hot flashes, head-
ache, and back pain [406]. The average wholesale cost for
a month's supply (thirty tablets) of aromatase inhibitors
is about $150 to $250 [407]. Table 6 lists the clinical
advantages of the third generation aromatase inhibitors as
regards potential use for ovarian stimulation.
Hypotheses behind the use of aromatase inhibitors for ovarian 
stimulation
In the late 1990s, we explored the hypothesis that it might
be possible to mimic the action of clomiphene citrate,
without depletion of ER, by administration of an aro-
matase inhibitor in the early part of the menstrual cycle.
We hypothesized that the result of blocking estrogen pro-
duction would be release of the hypothalamic/pituitary
axis from estrogenic negative feedback, thereby increasing
gonadotropin secretion and resulting in stimulation of
ovarian follicular development. This first hypothesis is
referred to as CENTRAL hypothesis. The selective non-
steroidal aromatase inhibitors have a relatively short half-
life (approximately 40 hours) compared to clomiphene
Table 5: The different degrees of whole body aromatase inhibition by the various aromatase inhibitors
Aromatase inhibitor Dose Mean percentage of total body aromatase 
inhibition
Aminoglutethimide in conjunction with 
hydrocortisone
1000 mg plus 40 mg of hydrocortisone (daily) 90.6
Formestane 250 mg (every 2 weeks, intramuscularly) 84.8
Exemestane 25 mg/day 97.9
Fadrozole 2 mg/day 82.4
Anastrozole 1 mg/day 97.3
Letrozole 2.5 mg/day >99.1
Vorozole 1 mg/day 93Reproductive Biology and Endocrinology 2005, 3:54 http://www.rbej.com/content/3/1/54
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citrate, and would be ideal for this purpose since they are
eliminated from the body rapidly [408,409]. In addition,
no adverse effects are expected on estrogen target tissues,
since no ER down-regulation occurs as observed in clomi-
phene citrate treatment cycles.
We subsequently developed a second hypothesis, which
was referred to as the PERIPHERAL hypothesis to explain
another mechanism of action of the aromatase inhibitors
in ovarian stimulation. We believe that aromatase inhibi-
tors also act locally in the ovary to increase follicular sen-
sitivity to FSH stimulation. This may result from the
temporary accumulation of intraovarian androgens, since
conversion of androgen substrate to estrogen is reversibly
blocked by aromatase inhibition. There are data support-
ing a stimulatory role for androgens in early follicular
growth in primates [410]. Testosterone was found to aug-
ment follicular FSH receptor expression in primates sug-
gesting that androgens promote follicular growth and
estrogen biosynthesis indirectly by amplifying FSH effects
[411,412]. In addition, androgen accumulation in the fol-
licle may stimulate insulin-like growth factor I (IGF-I),
along with other endocrine and paracrine factors, which
may synergize with FSH to promote folliculogenesis [413-
416]. This hypothesis still waits for evidence to support it.
1.2.1 Use of aromatase inhibitors alone for ovarian stimulation
In the last few years, we have worked on the development
of aromatase inhibitors for ovarian stimulation and infer-
tility management and reported interesting success in dif-
ferent applications as follows:
Induction of ovulation in anovulatory women
Based on our CENTRAL hypothesis of using an aromatase
inhibitor for induction of ovulation (as explained above),
the success of an aromatase inhibitor in inducing ovula-
tion in patients with PCOS was reported [417-420].
Augmentation of ovulation in ovulatory women
After demonstrating success in inducing ovulation in ano-
vulatory women, we proceeded to test whether aromatase
inhibition might enhance the release of endogenous
gonadotropins enough to stimulate the development of
multiple follicles in ovulatory women and result in aug-
mentation of ovulation or even controlled ovarian hyper-
stimulation. The use of an aromatase inhibitor for
augmenting ovulation in patients with ovulatory infertil-
ity was successful in women with unexplained infertility,
endometriosis, and women undergoing therapeutic
donor insemination, and in ovulating partners of infertile
men [419,420].
Induction and augmentation of ovulation after clomiphene citrate 
failure
For over 40 years, clomiphene citrate has been the most
commonly used treatment for the induction and augmen-
tation of ovulation, accounting for about two thirds of the
fertility drugs prescribed in the United States [421,422]. In
spite of the high ovulation rate associated with the use of
clomiphene citrate, the pregnancy rate is much lower than
anticipated. This is particularly true when considering
pregnancy rate per cycle after three cycles of CC treatment
[421], with higher than expected incidence of miscarriage
in conception cycles [255]. Such discrepancy is believed,
as explained earlier, to be due to the peripheral antiestro-
genic effect of clomiphene citrate particularly at the level
of the cervical mucus and endometrium, and which man-
ifest themselves even in the presence of gonadotropin
treatment superovulation. The accumulation in the body
of the isomers of clomiphene citrate due to the long half-
life (several days to weeks) adds to the persistence of the
antiestrogenic effect [261,262].
In order to improve the outcome of clomiphene citrate
treatment, various approaches have been suggested to
overcome the antiestrogenic effect including concomitant
estrogen administration. Some investigators reported
increased endometrial thickness and improved pregnancy
rates with this approach [423-425] while others have
reported no benefit [426] or even a deleterious effect of
estrogen administration [427]. Another approach was to
administer clomiphene citrate earlier during the men-
strual cycle [428], to allow the anti-estrogenic effect to
wear off earlier before the critical period of fertilization
and implantation. A third approach has been to combine
another selective ER modulator like tamoxifen, which has
more estrogen agonistic effect on the endometrium with
clomiphene citrate [429] or to use it as an alternative to
clomiphene citrate [430]. However, none of these strate-
gies have proved to be completely successful in avoiding
the peripheral antiestrogenic effects of clomiphene citrate.
In addition to a discrepancy between ovulation and preg-
nancy rates with clomiphene citrate treatment, 20% to
Table 6: Advantages of the third generation aromatase 
inhibitors:
• Extremely potent in inhibiting the aromatase enzyme
• Very specific in inhibiting the aromatase enzyme without significant 
inhibition of the other steroidogenesis enzymes
• Orally administered
• 100% bioavailability after oral administration
• Rapid clearance from the body (Short half-life, ~45 hours)
• No accumulation of the medications or their metabolites
• No significant active metabolites
• Well tolerated on daily administration for years
• Few side effects
• Very safe without significant contraindications
• Relatively inexpensiveReproductive Biology and Endocrinology 2005, 3:54 http://www.rbej.com/content/3/1/54
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25% of anovulatory women are resistant to clomiphene
citrate and fail to ovulate at doses up to 200 mg daily.
The success of aromatase inhibition in inducing and aug-
menting ovulation encouraged trying aromatase inhibi-
tors in cases of clomiphene citrate failure that was found
to be successful in achieving ovulation and pregnancy
[419,420]. As explained above, the significantly shorter
half-life of the third generation aromatase inhibitors com-
pared to clomiphene citrate, allows rapid elimination
from the body [408,409]. In addition, since no ER down-
regulation occurs, any adverse effects on estrogen target
tissues, as observed in clomiphene citrate treated cycles, is
expected.
1.2.2 Adjunct use of aromatase inhibitors for ovarian stimulation
We investigated the idea of combining an aromatase
inhibitor with FSH injections to reduce the dose of FSH
required to achieve optimum controlled ovarian
hyperstimulation, without adverse antiestrogenic effects
[431,432]. A significant reduction in the FSH dose
required (from 45% to 55% in women with PCOS and
unexplained infertility) has been reported [433] without
evidence of peripheral antiestrogenic effects [432,433].
Improving ovarian response to FSH stimulation in poor responders
Reducing FSH dose required for optimum controlled
ovarian hyperstimulation encouraged us to explore the
use of an aromatase inhibitor in conjunction with FSH to
improve response to ovarian stimulation in poor
responders. In a selected group of women who had a poor
response to FSH stimulation in at least two prior treat-
ment cycles, adding an aromatase inhibitor resulted in
improvement in the response to FSH stimulation. All
patients developed a significantly greater number of
mature ovarian follicles and almost a third of the treat-
ment cycles resulted in pregnancy. In addition, the dose of
FSH required to achieve such optimum response was sig-
nificantly less than the dose used in the prior cycles in
which FSH was used alone [434,435].
Developing alternative regimens for administering aromatase 
inhibitors for ovarian stimulation
During all the above-mentioned studies, the aromatase
inhibitor, letrozole, was administered orally as a daily
dose of 2.5 mg from day 3 to day 7 of the menstrual cycle.
Based on the pharmacokinetics of the new aromatase
inhibitors (almost 100% bioavailability after oral admin-
istration, ~2 days half-life and no accumulation or signif-
icant metabolite accumulation), we thought of a
potentially more convenient method of administering an
aromatase inhibitor for ovulation induction. We hypoth-
esized that significantly higher concentration of the aro-
matase inhibitor can be achieved early in the menstrual
cycle with faster clearance later in the menstrual cycle with
the administration of a high single dose of the aromatase
inhibitor early in the menstrual cycle such as on day 3. A
single dose regimen would satisfy two goals: first,
achieving maximum estrogen suppression early in the
menstrual cycle when it is desired, and second, to allow
clearance of the aromatase inhibitor before the critical
final stage of fertilization and embryogenesis, to maxi-
mize safety and avoid any possible undesirable effects of
the aromatase inhibitors. Single dose administration of an
aromatase inhibitor was found successful in inducing
ovulation with ovulation and pregnancy rates comparable
to the 5-day regimen [436].
Limitations of preliminary data on use of aromatase inhibitors for 
ovarian stimulation
In all our clinical trials described above, results were not
obtained from randomized, prospective, placebo control-
led studies, the optimum research design. However, due
to the experimental nature of the use of the aromatase
inhibitors for ovarian stimulation, which to our knowl-
edge, has never been used before, we believed that the
present observational trials were mandatory before pro-
ceeding into any definitive randomized studies.
The encouraging results of our data have led other investi-
gators from different centers world-wide to study the use
of aromatase inhibitors for ovarian stimulation and in
general have reported findings similar to ours in terms of
the success of aromatase inhibitors in infertility treatment
[437-450].
In a randomized, prospective study, a superior uterine
environment has been found in patients treated with an
aromatase inhibitor compared with clomiphene citrate,
reflecting the lack of the antiestrogenic effects with aro-
matase inhibitor treatment. Although a non-significant
increase in pregnancy was observed in patients who
received aromatase inhibitor treatment (16.7 versus 5.6%
per patient, P = 0.55), this almost three-fold increase in
pregnancy rate would have required about ten more
patients per group to reach statistical significance. The
superiority of a single dose administration of an aro-
matase inhibitor was also reported when compared to clo-
miphene citrate [439]. In other studies, the use of an
aromatase inhibitor in conjunction with FSH was found
to reduce the FSH dose [440] and improve response to
ovarian stimulation in poor responders [441,442], con-
firming our previous reports.
In another prospective randomized trial, Biljan [438]
studied two doses (2.5 and 5 mg per day) of the aromatase
inhibitor, letrozole for ovarian stimulation in patients
with unexplained infertility. They found patients treated
with a higher dose of letrozole developed more follicles
without a detrimental effect on endometrial develop-Reproductive Biology and Endocrinology 2005, 3:54 http://www.rbej.com/content/3/1/54
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ment. The potential for different doses and regimens of
administration of aromatase inhibitors for ovarian stimu-
lation still requires a lot of study, but the use of aromatase
inhibitors at high doses should be cautiously considered.
In all reports and most of studies of other investigators,
the aromatase inhibitor, letrozole was the one used. How-
ever, anastrozole, another third generation aromatase
inhibitor similar to letrozole, was used in other studies
[443,444]. Due to the similar pharmacokinetics and phar-
macodynamics, including similar potencies and specifi-
city in inhibiting the aromatase enzyme, we believe there
is likely to be no difference between the third generation
aromatase inhibitors in their efficacy for ovarian stimula-
tion. It does, however, need to be determined what dose
of anastrozole is required to be equivalent to letrozole.
Future avenues for the use of aromatase inhibitors for infertility 
management
It seems that there are many interesting areas of research
that need exploration as regards the development of aro-
matase inhibitors for infertility management. These direc-
tions for research would include: confirming the available
preliminary data on the success of aromatase inhibition in
induction and augmentation of ovulation, as well as
reducing the dose of FSH needed for ovarian stimulation,
improving response in poor responders, and finding the
optimum regimen for administering aromatase inhibitors
for infertility treatment
Moreover, the use of aromatase inhibitors for new appli-
cations including in-vitro maturation and prevention of
severe ovarian hyperstimulation syndrome and endome-
triosis-related infertility are interesting future avenues for
aromatase inhibitors potential use in infertility
management.
In addition the use of aromatase inhibitors to improve the
outcome of treatment after assisted reproduction as dis-
cussed earlier in this review is an exciting area of
application.
1.3 Use of aromatase inhibitors to improve treatment outcome after 
ovarian stimulation and assisted reproduction
In addition to using aromatase inhibitors, ALONE, for
ovarian stimulation, their use during assisted reproduc-
tion carries several potentials to improve the treatment
outcome.
Improving implantation rates
We hypothesize that aromatase inhibition during assisted
reproduction may improve the implantation rate mainly
by reducing the estrogen levels attained during COH. In
addition, two other mechanisms may apply including
reducing the dose of FSH required for optimum COH as
well as applying much simpler stimulation protocols that
do not require the use of GnRH analogues, hence
avoiding any possible direct deleterious effects of FSH and
GnRH analogues on the endometrium.
1.3.1 Lowering supraphysiological estrogen levels
As discussed above, the undesirable effects of ovarian
stimulation on the outcome of infertility treatment are
believed to be due to the supraphysiological levels of
estrogen irrespective to whatever mechanisms explain for
that (various postulated mechanisms were discussed
above). So, lowering estrogen levels may be associated
with improved outcome of treatment in terms of improv-
ing the implantation and pregnancy rates in addition to
lowering risk of sever ovarian hyperstimulation
syndrome.
Reducing estrogen synthesis by aromatase inhibition
seems to be an exciting idea to ameliorate the deleterious
effects of the supraphysiological levels of estrogen on the
endometrium, the developing oocyte and embryo as well
as the luteal.
Until recently there was no suitable aromatase inhibitor
that could be used clinically to reduce estrogen levels dur-
ing ovarian stimulation. This is because the available aro-
matase inhibitors were not safe for clinical application
during ovarian stimulation due to lack of specificity in
inhibiting the aromatase enzyme without inhibiting other
steroidogenesis enzymes (e.g. aminoglutethimide). The
other aromatase inhibitors (steroidal androstenedione
analogues) were irreversible in their effect on the aro-
matase enzyme besides being parentrally administered.
Most important, these old aromatase inhibitors were not
potent enough to inhibit the aromatase enzyme and lower
estrogen levels in women of the reproductive age group.
However, the third generation non-steroidal aromatase
inhibitors group is very potent and specific in inhibiting
the aromatase enzyme reversibly. These new aromatase
inhibitors are orally administered with very high safety
profile and well tolerability. Moreover, they are cheap
with a relatively short half-life [~45 hours], and already
approved for clinical use to reduce estrogen production in
postmenopausal women with breast cancer.
They have not been used in women of the reproductive
age group. However, we have found these aromatase
inhibitors to be effective in inhibiting the aromatase
enzyme and effectively decrease estrogen levels in women
of the reproductive age group during their successful use
for ovarian stimulation [417,418,431,432].
In our experience with the use of an aromatase inhibitor
for ovarian stimulation, estrogen levels were significantly
lower (especially E2 level/mature follicle) when comparedReproductive Biology and Endocrinology 2005, 3:54 http://www.rbej.com/content/3/1/54
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with conventional stimulation protocols (clomiphene cit-
rate, FSH and clomiphene citrate plus FSH). Such low E2
levels may be beneficial and explains at least partially the
improved outcome of treatment in terms of achieving
promising high pregnancy rates during aromatase inhibi-
tor treatment.
It may not be only the supraphysiological estrogen levels,
which explain totally for the reduced implantation rate
during ovarian stimulation cycles. Local paracrine factors,
or possibly other undetermined factors may be responsi-
ble for the reduced implantation rate during COH. In this
case the aromatase inhibitors may not offer a complete
solution to overcome such drawbacks of ovarian stimula-
tion. However, the idea is exciting and seems to be prom-
ising and warrant trials because high estrogen levels may
explain, at least in part, for the deleterious effects of ovar-
ian stimulation on treatment outcome.
In ddition, we think that, reducing estrogen levels
achieved during induction of ovulation by using aro-
matase inhibitors may prevent the significant increase in
leptin concentrations avoiding its possible deleterious
effects on the outcome of treatment as explained above.
Because elucidation of leptin's specific role in reproduc-
tive function has been challenging, with conflicting results
reported by various investigators, it is still quite early and
highly speculative to hypothesize a link between aro-
matase inhibitors use and the role of leptin during induc-
tion of ovulation. However, the available strong data
about a possible role of leptin in mediating reproductive
disorders especially in obese women and the firm findings
of a regulatory effect of estrogen on leptin production
make this hypothesis exciting and interesting enough to
warrant future investigation.
1.3.2 Reducing gonadotropins requirements for optimum ovarian 
stimulation
As mentioned earlier, the use of an aromatase inhibitor
significantly reduces the dose of FSH required for opti-
mum COH. In addition to the significant economic ben-
efit, we believe that reducing the dose of FSH may
improve the treatment outcome of ovarian stimulation by
reducing any possible deleterious effect of the exoge-
nously administered FSH on the endometrium, develop-
ing oocyte or other targets.
Other possible benefits
It is believed that the endogenous LH surge arises once
serum estrogen levels surpass a set threshold for a certain
period of time [451-453].
The supraphysiological estrogen levels attained during
ovarian stimulation are believed to cause premature
release of the endogenous LH surge resulting in cycle can-
cellation during assisted reproduction. For that reason,
GnRH analogues have been the standard of practice
during most of the stimulation protocols for assisted
reproduction to prevent the occurrence of endogenous LH
surge either by direct inhibition of LH surge (GnRH antag-
onists) or by down-regulation of the GnRH receptors at
the pituitary levels resulting in pituitary desensitization
and prevention of the release of endogenous LH
[454,455].
Unfortunately, the use of GnRH analogues (which is a
crucial part of the stimulation protocol to prevent cycle
cancellation as explained above), is associated with sev-
eral problems including increasing the dose of FSH
required to achieve optimum COH (due to suppressing
the endogenous gonadotropin secretion, and possible
peripheral effect at the level of the ovaries), as well as the
luteal phase defect due to a dysfunctional corpus luteum
function secondary to persistent endogenous LH suppres-
sion as explained earlier. In addition, there is rising evi-
dence of a possible direct deleterious effect of the GnRH
analogues, especially the antagonist at the level of the
endometrium [456].
The use of an aromatase inhibitor to reduce estrogen lev-
els attained during COH may be effective in preventing
the occurrence of premature ovarian surge. This would
avoid the use of GnRH analogues during stimulation pro-
tocols for assisted reproduction which has several advan-
tages including prevention of the possible deleterious
effects of these agents as mentioned above in addition to
reducing the cost of treatment as well allowing imple-
menting much simpler stimulation protocols during
assisted reproduction.
Aromatase inhibitors for endometriosis-related infertility
The expression of aromatase enzyme in endometriotic tis-
sues with the significant role of locally produced estrogen
in endometriosis progression [457] suggests a benefit of
aromatase inhibitors in endometriosis-related infertility.
The inhibition of local estrogen production in endome-
trial implants, and the lower peripheral estrogen levels
associated with the use of aromatase inhibition for ovula-
tion induction, is expected to protect, to some degree,
against progression of endometriosis during infertility
treatment.
1.4 Concerns regarding the use of aromatase inhibitors in infertility 
treatment
There are three main concerns that may arise regarding the
use of the aromatase inhibitors to improve the outcome of
treatment after ovarian stimulation and assisted reproduc-
tion. They include the possible deleterious effect of the
low follicular estrogen milieu on the development of the
oocytes, the possible direct effect of the aromatase inhibi-Reproductive Biology and Endocrinology 2005, 3:54 http://www.rbej.com/content/3/1/54
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tors on the oocyte development, fertilization or embryo-
genesis, and the accumulation of the androgens that may
result from inhibition of their conversion into estrogens.
1.4.1 Effect of low estrogen milieu on the developing oocyte
Palter et al. have reviewed the question whether an estro-
gen-free (or at least very low estrogen) intrafollicular envi-
ronment is compatible with follicular development,
ovulation, and corpus luteum formation [458]. The
authors concluded that markedly reduced to nonexistent
intrafollicular and circulating concentrations of estrogen
are compatible with follicular "expansion", retrievable
and fertilizable oocytes, as well as with cleavable and
apparently transferable embryos. The authors drew their
conclusion after discussing lessons from data in the liter-
ature including cases of deficiency of the 17-hydroxylase/
17–20 lyase [459-466] and 3β-hydroxysteroid dehydroge-
nase [467,468] and the aromatase enzyme [469-473] as
well as cases of severe hypogonadotropism [474-478]. In
addition, data on the use of aromatase inhibitors in ani-
mals were reviewed [479-482].
Cases of enzyme deficiency leading to a status of very low estrogen 
levels
17 alpha-hydroxylase/17–20 lyase deficiency
17alpha-hydroxylase/17–20 lyase deficiency is one form
of congenital adrenal hyperplasia, which is associated
with marked impairment of glucocorticoid, androgen,
and estrogen biosynthesis [459]. Women suffering from
this enzyme deficiency suffer from hypergonadotropic
hypogonadism and sexual infantilism. However, early
reports noted the presence of many primary and second-
ary follicles in ovarian material [460] and many of them
had bilateral multicystic ovaries at the time of laparotomy
[461-463].
It is interesting that Rabinovici reported on a patient
afflicted with virtually complete 17-hydroxylase/17–20
lyase deficiency that, despite castrate levels of estrogens,
underwent an apparently successful induction of ovula-
tion associated with progressive follicular expansion and
oocyte retrieval, IVF-ET, and early embryonic cleavage fol-
lowed suit [464].
3β-hydroxysteroid dehydrogenase [3β-HSD] deficiency
The deficiency of 3β-HSD is associated with markedly
reduced levels of estrogen. However, the existence of nor-
mal ovulatory function in a woman with late-onset of a
mild form of 3β-HSD has been reported [483].
In a group of cycling female Rhesus monkeys exposed to
ovulation induction with hFSH and hFSH + hLH in the
absence or presence of the 3β-HSD inhibitor trilostane
given on days 1–8 of the menstrual cycle [467], appar-
ently healthy oocytes were obtained by follicular aspira-
tion 34 h after hCG administration. Importantly,
treatment with the 3β-HSD inhibitor, trilostane, led to a
reduction in serum E2 levels to 7% of that of control ani-
mals throughout the follicular phase. Despite this dra-
matic reduction in E2 levels, neither the total number of
large antral follicles per animal (17 ± 1 vs. 18 ± 2) nor
their size distribution differed significantly from 3β-HSD
inhibitor-untreated controls. Furthermore, treatment with
the 3β-HSD inhibitor did not alter the overall maturation
pattern of collected oocytes (atretic, prophase I, met-
aphase I, or metaphase II). However, the authors found a
reduction in the percentage of metaphase II oocytes that
were successfully fertilized (15 vs. 65%). Moreover, met-
aphase oocytes that required more than 8 h to complete
meiosis in vitro failed to fertilize in three of four animals
receiving 3β-HSD inhibitor relative to controls (31%).
These observations suggest that follicular development
and the completion of meiosis may be unaffected by the
low estrogen levels but that cytoplasmic oocyte matura-
tion and/or function could be unfavorably affected [467].
Aromatase enzyme deficiency and the use of aromatase inhibitors
Obviously, aromatase (estrogen synthase) enzyme defi-
ciency is associated with marked decrease or almost
absence of estrogen production.
Extreme examples of complete aromatase deficiency due
to mutations in the aromatase gene, CYP19 gene, in adult
human females, however, were reported [469,470]. The
affected patients suffered from ambiguous external genita-
lia, primary amenorrhea, sexual infantilism, and multi-
cystic ovaries.
Morishima [471] reported on the aromatase deficiency in
a 28-yr-old 46 XX proband followed since infancy. Null
mutant mice for aromatase gene [ArKO] were generated
[484], thereby affording the opportunity to examine the
role of estrogen in the follicular development in the
mouse ovary. Evaluation of the ovaries revealed the pres-
ence of many large follicles filled with granulosa cells and
evidence of antrum formation, but no corpora lutea. The
ovarian phenotype degenerated with age upon the
appearance of hemorrhagic cystic follicles and the loss of
secondary and antral follicles coincident with the infiltra-
tion of macrophages and with stromal hyperplasia [485-
488]. Therefore, the ArKO females are infertile, due pri-
marily to a complete lack of ovulation.
However, recently, Jones et al., reported that oocytes were
harvested from the ovaries of 4- and 7-week old ArKO,
wild type and heterozygote mice stimulated with 5 IU
PMSG. The number of immature oocytes harvested from
ArKO females did not differ from the number collected
from wild type or heterozygote littermates of either age
group. Oocyte in vitro maturation rates also did not differReproductive Biology and Endocrinology 2005, 3:54 http://www.rbej.com/content/3/1/54
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between the three genotypes or two age groups, with
almost 75% of the immature oocytes progressing to met-
aphase II. Chromatin staining confirmed the arrest of
these oocytes at the second meiotic division with chroma-
tin staining clearly present in the oocyte and polar body.
Mature oocytes were inseminated and IVF-ET rates did not
differ between the three genotypes or two age groups, with
fertilization occurring in approximately 67% of oocytes.
Fertilized oocytes were cultured to blastocysts. Again,
blastocyst development rates did not differ between the
groups, with approximately 65% of the zygotes develop-
ing into blastocysts. Blastocyst morphology was similar
across all of the groups [489].
These results indicate that ArKO oocytes are competent to
develop to at least the implantation stage. The authors
concluded that estrogen might not be required for the
production and maturation of developmentally compe-
tent oocytes. Rather, its role in folliculogenesis is probably
via regulation of the hypophysial pituitary gonadal axis
and thus gonadotropin secretion [489].
Regarding the effect of an estrogen-free/poor intrafollicu-
lar environment on gametogenic maturation, Palter et al.
[458] concluded that the effect is a negative one. Their
conclusion was based on a number of primate studies,
which indicated that an estrogen-free/poor intrafollicular
environment is associated with marked decrements in the
rates of meiotic maturation and fertilization [467,490]. In
addition data derived from rodent models suggested that
further suggested a compromise in early embryonic devel-
opment [491].
In cycling female rhesus monkeys, the aromatase inhibi-
tor, 1,4,6-androstatrien-3, 17-dione (ATD) was used to
inhibit estrogen production during gonadotropin ovarian
stimulation [479]. Animals treated with ATD displayed a
drastic reduction in serum 17β-E2 levels to 37% of that of
controls within 8 h of ATD treatment and to 16% of con-
trol by the day of hCG injection. In turn, the circulating
levels of androstenedione rose. Despite the drastic
reduction in the circulating levels of E2 and the increase in
the circulating levels of androgens, the overall number of
large antral follicles [16 ± 3 for controls and 20 ± 3 for
ATD-treated] and their size distribution (as assessed by
ultrasonography) proved comparable for control and
ATD-treated animals. Similarly, no difference was noted
in the number of oocytes collected or in the proportion of
oocytes reinitiating meiosis (MI at the time of collection).
In contrast, ATD-treated animals displayed a marked
increase (31 vs. 11%) in the proportion of prophase I
oocytes. Moreover, ATD-treated oocytes displayed
retarded in vivo completion of maturation to MII (4% vs.
26%). Interestingly, the latter retardation was not
observed in vitro. Furthermore, two of the four ATD-
treated animals yielded oocytes that were
morphologically abnormal. Finally, oocytes from ATD-
treated animals displayed significantly reduced rates of
fertilization (9% vs. 25%) as compared with controls.
However, the cleavage rate after successful fertilization
was similar for ATD-treated vs. ATD-untreated controls. In
vitro cultures of granulosa cells collected at the time of
oocyte aspiration revealed equivalent 24-h progesterone
production in treated and control animals. The authors
concluded that these findings suggest that the acute reduc-
tion in E2 levels during the terminal stage of gonadotropin
stimulation had little effect upon follicular recruitment
and expansion but an apparent detrimental effect upon
gametogenic function may, in fact, exist. However, we
cannot extrapolate from this study that the findings are
simply due to the acute reduction of estrogen production
as it is important to realize that there was a concomitant
significant rise in androstenedione. Moreover, the time of
administering an aromatase inhibitor during the latter
part of the follicular phase as well as the irreversible
nature of aromatase inhibition constitute important dif-
ferences from our model of using a REVERSIBLE aro-
matase inhibitor, TEMPORARILY, EARLY in the menstrual
cycle that has a SHORT half-life.
Selvaraj [480,481] and Shetty [482] examine the effects of
blocking estrogen biosynthesis during the follicular phase
on follicular maturation in the adult female bonnet mon-
key. In their studies, they used one of the third-generation
REVERSIBLE, aromatase inhibitors (CGS 16949A) start-
ing EARLY on day 3 of the menstrual cycle. There were
53% and 70% reductions in the basal and surge levels of
E2, respectively without obvious effect on follicular matu-
ration, ovulation, and luteal function as assessed by
serum hormone profiles as well as by laparotomy. More-
over, the concurrent administration of FSH and an aro-
matase inhibitor resulted in the suppression of the FSH-
induced increase in the circulating levels of E2 (by 100%)
with no effect noted on either the number of follicles
developed or their size relative to control. In addition,
granulosa and theca cells, removed on day 9 of the treat-
ment cycle, were responsive to gonadotropins in vitro,
disclosing no evidence of a deleterious effect on the cellu-
lar development and maturation of follicular cells.
Terry studied a possible role of high E2 levels in mediating
the adverse effects of hyperstimulation with PMSG on
early embryonic development in the rat [491]. They used
the aromatase inhibitor, 4-hydroxyandrostenedione (4-
OHA), to inhibit endogenous E2 production. The authors
conducted three experiments. In the first, varying doses of
4-OHA were administered either concurrently with hCG
to pro-estrus female rats hyperstimulated at early diestrus
stage with 20 IU PMSG or alone into non-hyperstimu-
lated pro-oestrus females. At high doses of 1000, 2000, orReproductive Biology and Endocrinology 2005, 3:54 http://www.rbej.com/content/3/1/54
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5000 mg/rat, 4-OHA substantially improved the survival
of embryos in hyperstimulated females with optimum
protection at 2000 mg, while low doses of 100 and 500
mg/rat were ineffective. When administered alone, only
the highest dose of 5000 mg/rat 4-OHA increased embryo
count. In the second experiment, higher doses of PMSG
were studied (30 or 40 IU), with or without 5000 mg/rat
4-OHA given at the time of hCG injection. PMSG proved
to be more detrimental with increasing dose, and high
doses of 4-OHA (5000 mg/rat) was needed to rescue
embryos from death in the 30, but not 40, PMSG group.
In the third experiment, the influence of the timing of 4-
OHA treatment on its ability to improve the embryo
count in hyperstimulated females was examined by intro-
ducing 4-OHA 24 h earlier, rather than at the time of hCG
treatment. The results showed the importance of timing of
4-OHA administration, as 5000 mg/rat 4-OHA was able
to restore embryo survival in the 40 PMSG hyperstimu-
lated group only when it was administered 24 h before
hCG injection. These results highlighted that 4-OHA,
when administered at the appropriate time and dose,
could reverse the negative effects of hyperstimulation
from PMSG on early embryonic development. The
authors concluded that this might be due to the suppres-
sion of estrogen production, thereby alleviating the supra-
physiological level of E2, which is typically present in
PMSG-treated females, which supports the hypothesis
that excessive E2 is responsible for the negative effects of
hyperstimulation with PMSG on early embryonic
development.
The high success rates of ovulation and achievement of
pregnancy in our reports on the use of aromatase inhibi-
tor in ovarian stimulation, despite significantly lower
estrogen levels could be due to several reasons. First: We
used one of the third-generation "REVERSIBLE" aro-
matase inhibitors. Second: The aromatase inhibitor was
administered EARLY in the follicular phase and for a lim-
ited period of time, which would allow the rapid clear-
ance of the aromatase inhibitor from the body due to its
SHORT half-life. Third: the reversible nature of the
aromatase enzyme inhibition and the rising levels of FSH,
which induce the expression of the aromatase enzyme,
both would not allow for the estrogen levels to drop dras-
tically below the low physiologic range. We believe that
these low estrogen levels attained during the use of aro-
matase inhibitors for ovarian stimulation are compatible
with healthy development of the oocytes, fertilization,
embryo development, implantation and achievement of
pregnancy. Fourth: the absence of significant rise in
androgen levels would have prevented any possible
unwanted effects on the terminal part of the oocyte matu-
ration and ovulation.
1.4.2 Direct effect of the aromatase inhibitors on the developing 
oocyte, fertilization and embryogenesis
As explained above, the short half-life of the aromatase
inhibitors and limiting the administration to the early
part of the follicular phase would allow the rapid clear-
ance of the medications from the body before the impor-
tant stage of fertilization and embryogenesis. This in
addition to the absence of accumulation of the aromatase
inhibitors of any of their metabolites would make them
safe for the ovarian stimulation. We have reported a pre-
liminary data on the pregnancy outcome after the use of
aromatase inhibitors for ovarian stimulation supporting
the safety of using these medications for such indication
[492].
Data have been accumulating regarding the absence of
deleterious effects in association with aromatase inhibitor
treatment on follicle/oocyte maturation and embryo
development in mice [492,493]. Treatment with the aro-
matase inhibitor, anastrozole was associated with similar
number of total follicles found per animal (30.4 follicles/
animal in the control group and 27 follicles/animal in the
anastrozole-treated group) as well as comparable rates of
development of embryos, morulae, blastocysts, and
hatching blastocysts between the two groups (P = 0.20,
0.10, 0.44, and 0.38, respectively) [493].
1.4.3 Effect of the accumulated androgens
As mentioned before, the rapid clearance of the aromatase
inhibitors from the body due to their short half-life and
the reversible nature of the aromatase enzyme inhibition
as well as the rising levels of FSH, which induce the expres-
sion of the aromatase enzyme, all would not allow the
clearance of any accumulating androgens by converting
them to estrogen. The conversion of the androgens into
estrogens (the step catalyzed by the aromatase enzyme) is
a terminal step in the cascade of steroidogenesis. So, sub-
strate (androgens) accumulation is not expected to be very
significant, as other alternative earlier steps in the ster-
oidogenesis pathways will work to clear out the accumu-
lating androgens. For these reasons, pharmacokinetic
studies on the new aromatase inhibitors reported the
absence of significant androgen elevations or abnormal
changes in other steroids in patients receiving aromatase
inhibitors for breast cancer. In a subset of our patients
who received an aromatase inhibitor for ovarian stimula-
tion, we did not find significant change in the androgen
levels while receiving the medication when compared to
stimulation with gonadotropins alone (unpublished
data).
Most recently we published data on the favorable preg-
nancy outcome after the use of letrozole for ovarian stim-
ulation alone or in conjunction with gonadotropins
[494]. This study looked at outcome of pregnanciesReproductive Biology and Endocrinology 2005, 3:54 http://www.rbej.com/content/3/1/54
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achieved after ovarian stimulation with the aromatase
inhibitor, letrozole, alone or in conjunction with gonado-
tropins. The study included a cohort of 394 pregnancy
cycles achieved after letrozole and other ovarian stimula-
tion treatments in a ddition to a control group of pregnan-
cies spontaneously conceived without ovarian
stimulation. These 394 pregnancy cycles were achieved as
follows: 63 pregnancies with 2.5 mg of letrozole alone or
with gonadotropins, 70 pregnancies with 5.0 mg of letro-
zole, 113 pregnancies with clomiphene alone or with
gonadotropins, 110 pregnancies with gonadotropins
alone, and 38 pregnancies achieved without ovarian stim-
ulation. The study found pregnancies conceived after
letrozole treatments were associated with similar miscar-
riage and ectopic pregnancy rates compared with all other
groups. In addition, letrozole use was associated with a
significantly lower rate of multiple gestation compared
with clomiphene citrate. The findings of the stuy support
the favorable pregnancy outcome and low multiple gesta-
tion rate in association with the use of aromatase inhibi-
tors for ovarian stimulation [494].
5 Summary and conclusion
Ovarian stimulation particularly in conjunction with
assisted reproductive technologies aims at stimulating the
recruitment of several mature ovarian follicles that would
enhance the chance of successful treatment by obtaining
several embryos readily available for transfer into the
uterus. It is obvious that supraphysiological levels of
estrogen are inevitably attained during ovarian stimula-
tion due to the significant contribution of estrogen pro-
duction from each one of the several mature ovarian
follicles. There is growing evidence that such supraphysi-
ological estrogen levels are deleterious on the develop-
ment of the endometrium, oocytes, embryos as well as
other targets through different mechanisms. This is
believed to explain, at least in part, the low pregnancy
rates associated with assisted reproduction, mainly as a
result of the persistently low implantation rates that have
not improved impressively along almost three decades of
assisted reproduction experience. This led several investi-
gators to adopt the concept of minimal ovarian
stimulation for assisted reproduction as an alternative
approach to reduce the deleterious effects of the supra-
physiological estrogen levels attained during routine con-
trolled ovarian hyperstimulation. Unfortunately such
approach, despite being logical, is associated with the
major drawback of achieving fewer oocytes than desired,
which, expectedly, reduces the chances of treatment suc-
cess. Recently, we reported the success of the new genera-
tion aromatase inhibitors in ovarian stimulation. We
found these agents to be effective in reducing the amount
of estrogen production by mature ovarian follicles signif-
icantly. Furthermore, we found the use of these agents to
be associated with improved ovarian response to stimula-
tion by gonadotropins, resulting in significant reduction
in the dose of gonadotropins required for controlled ovar-
ian hyperstimulation. The novel idea of using aromatase
inhibitors during ovarian stimulation for assisted repro-
duction combines the benefit of a significant reduction in
estrogen production as well as gonadotropins dose, with
the exiting advantage of achieving a good number of
mature oocytes as a result of enhanced ovarian response
to gonadotropins. This is expected to improve the various
aspects of treatment outcomes after assisted reproduction
including increased safety, reduced cost, as well as
enhanced implantation rate. If confirmed in well-
designed clinical trials, this would facilitate acceptance of
the concept of single embryo transfer by infertile couples
and practitioners, thereby reducing the epidemic of mul-
tiple births after assisted reproduction with its significant
deleterious health and economical effects. This is particu-
larly true in the light of recent data supporting the success
of the approach of single embryo transfer [495-497].
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